University of Central Florida

STARS
Electronic Theses and Dissertations, 2004-2019
2007

Lim Kinase 1 Modulates Expression Of Matrix Metalloproteinases
And Associates With Gamma-tubulin: Dual Role In Invasion And
Mito
Tenekua Tapia
University of Central Florida

Part of the Cancer Biology Commons, Microbiology Commons, and the Molecular Biology Commons

Find similar works at: https://stars.library.ucf.edu/etd
University of Central Florida Libraries http://library.ucf.edu
This Masters Thesis (Open Access) is brought to you for free and open access by STARS. It has been accepted for
inclusion in Electronic Theses and Dissertations, 2004-2019 by an authorized administrator of STARS. For more
information, please contact STARS@ucf.edu.

STARS Citation
Tapia, Tenekua, "Lim Kinase 1 Modulates Expression Of Matrix Metalloproteinases And Associates With
Gamma-tubulin: Dual Role In Invasion And Mito" (2007). Electronic Theses and Dissertations, 2004-2019.
3378.
https://stars.library.ucf.edu/etd/3378

LIM KINASE 1 MODULATES EXPRESSION OF MATRIX
METALLOPROTEINASES AND ASSOCIATES WITH γ-TUBULIN: DUAL
ROLE IN INVASION AND MITOTIC PROCESSES

by
TENEKUA MARIE TAPIA
B.S. Xavier University of Louisiana, 2001

A thesis submitted in partial fulfillment of the requirements
for the degree of Master of Science
in the Department of Molecular Biology and Microbiology
in the Burnett College of Biomedical Sciences
at the University of Central Florida
Orlando, Florida

Summer Term
2007

ABSTRACT
LIM kinase 1 (LIMK1) is a unique dual specificity serine/threonine kinase containing
two N-terminal LIM domains in tandem, a PDZ domain and a C-terminal catalytic domain.
LIMK1 is involved in modulation of actin cytoskeleton through inactivating phosphorylation of
the ADF (actin depolymerization factor) family protein cofilin. Recent studies have shown that
LIMK1 is upregulated in breast and prostate cancer cells and tissues, promotes metastasis in
animals and induces acquisition of an invasive phenotype when ectopically expressed in benign
prostate epithelial (BPH) cells. Furthermore, overexpression of LIMK1 was associated with
altered sub cellular localization of the membrane type 1 matrix metalloprotease (MT1-MMP).
Matrix metalloproteases (MMPs) are a family of zinc dependant proteolytic enzymes that
hydrolyze extra cellular matrix and cell surface molecules. A number of MMPs including MMP2, MMP-9 and their activator MT1-MMP are over expressed in a variety of cancers including
prostate cancer. The abundant expression of these enzymes contributes to changes in the tumor
microenvironment, which facilitate degradation of the surrounding collagen matrix and
migration of cells through the matrix defects. In this study, we show that MMPs are involved in
LIMK1 induced invasion of otherwise non-invasive BPH cells. We also show that (a) the kinase
activity of LIMK is not essential for the invasive behavior of the cells and (b) the absence of
LIM domains significantly retards cell invasion. We have established transfected sub lines of
BPH cells stably expressing 1) constitutively active LIMK1 (BPHLCA), 2) kinase dead LIMK1
(BPHLKD) and 3) only the kinase domain of LIMK1 (BPHLK) for our study. In vitro invasion
assays revealed that LIMK1 induced invasion was inhibited by the MMP specific inhibitor,
GM6001, and that cells expressing kinase-dead LIMK1 were equally invasive. Furthermore,
ii

BPH cells expressing LIMK1 mutants expressed higher amounts of MMP-2 and MMP-9.
Substrate zymography revealed increased concentration of secreted MMP-2 and MMP-9 in the
media of BPHLCA and BPHLK cells respectively compared to BPHV (vector control) cells.
Quantitative RT-PCR also showed a ~10 fold increase in the steady state concentration of MMP2 in BPHLCA cells compared to the control BPHLV cells. Expression of active LIMK1 stimulated
cell-surface expression of MT1-MMP in BPHLCA cells as determined by flow cytometry. A
modest increase in expression of MT1-MMP was noted in BPHLKD cells compared to BPHLK
and BPHV cells. Immunoflourescence analysis indicated differential localization of MT1-MMP
and LIMK1 in BPH cells expressing different mutants of LIMK1. Co-localization of LIMK1
and MT1-MMP in the plasma membrane and in the perinuclear region was also evident in these
cells. Furthermore, here we provide evidence that suggests a functional role for phosphorylated
(activated) LIMK1/2 (p-LIMK1/2) during mitosis through its association with γ-tubulin.
Immunoflourescence analysis showed distinct co-localization of γ -tubulin and p-LIMK1/2 in the
centrosomes during mitosis from early prophase to the beginning of telophase. No association
was seen in the interphase or in late telophase. Phospho-LIMK1/2 was co-precipitated in
immunoprecipitates of γ -tubulin using an anti- γ -tubulin antibody suggesting a physical
association between these proteins in a complex. This finding reveals a novel role of LIMK1 in
the mitotic process.
In summary, our data suggests that MMPs are involved in LIMK1 induced invasion of
prostate epithelial cells, and that this effect is mediated through altered expression and activation
of specific MMPs. Furthermore, LIMK1 induced invasion is dependant on the presence of LIM
domains more than the kinase activity. Finally, we show that phosphorylated LIMK1 and
iii

LIMK2 are involved in the mitotic process in a stage specific manner through its association
with the centrosomal protein γ -tubulin. Because LIMK1 promotes invasion in vitro, regulates
expression of MMPs, and is involved in mitotic processes, it is an attractive drug target for
prostate cancer therapy.
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1. INTRODUCTION
1.1 Facts about Prostate Cancer
Prostate cancer is the second most deadly cancer in men after lung cancer in the United States
and the sixth leading cause of death of men overall [Ward-Smith, 2006] . In fact, one in every
six men will be diagnosed with the disease at some point in their life (Figure 1). Prevalence rates
of prostate cancer remain significantly higher in African Americans compared to white men and
Hispanics [Theodorescu and Pollack, 2003]. Furthermore, mortality rates for African Americans
are at least doubled compared to men of other racial and ethnic groups. In addition, family
history is one of the strongest risk factors for prostate cancer [Paiss et al., 2006]. The 5-year
relative prostate cancer survival rate for men with localized prostate cancer is 100%; however
men with advanced stage of the disease have only a 33% chance of survival. Prostate cancer is
mainly diagnosed in men over age 65, nonetheless younger populations are also susceptible to
the disease. It affects all racial/ethnic groups and is a major health concern.
1.2 Stages of the Disease
The prostate rests in the pelvis (Figure 2) and is made up of branching glands with ducts that are
lined with secretory epithelial cells and basal cells [McNeal, 1988]. Prostate cancer is a disease
in which the epithelial cells that line the prostate gland mutate and begin to proliferate without
regulation. It is divided into six stages [Savage et al., 1997]. Stage 1 (T1) cancer is localized
only in the prostate. Stage 2 (T2) cancer is still localized in the prostate gland, but is larger in
size. Stage 3 (T3) cancer is no longer confined to the prostate gland, but is larger in size.

1

Figure 1 Prostate Cancer Distribution
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Figure 2 Anatomy of the Prostate
The prostate gland is located below the bladder and surrounds the upper portion of the urethra.
Oregon Health and Science University health center. medicalcenter.osu.edu/
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Stage 3 (T3) cancer is no longer confined to the prostate but has spread to nearby seminal
vesicles. Stage 4 (T4) cancer is detected in tissues far from the prostate, including lymph nodes
(Stage N+) or even bone (Stage M+). Symptoms when present, may include, frequent and
painful urination, blood or semen in urine, erectile dysfunction and pain or stiffness in lower
back, hips or thighs. There are several tests available for the screening and diagnosis of prostate
cancer; these include PSA test, digital rectal exam, MRI scan, ultrasound, CT scan and biopsy.
Of these, PSA test combined with digital rectal exam are routinely performed. The PSA test
measures the concentration of PSA (prostate specific antigen) in blood; which increases in men
who have prostate cancer. In the digital rectal exam, the physician indirectly assesses the
prostate tissue for irregularity and roughness.

It is recommended that men over age 50 have

PSA test and DRE done yearly [Rinnab et al., 2005].
1.3 Treatments
The treatment options for prostate cancer are dictated by the stage of the cancer. In some cases
of “early staged” cancer, treatment is withheld until symptoms appear or change. Treatments for
stage 1 and 2 prostate cancer include radiation therapy, cryotherapy, prostatectomy and
transurethral resection of the prostate (TURP). The goal of these treatments is to destroy cancer
cells before they spread to the rest of the body. Hormone therapy (also called anti-androgen
treatment) is the treatment option of choice for stage 3, stage 4 and stage N+ prostate cancer.
This option is effective in slowing the rate of cancer growth by inhibiting hormones necessary
for growth, development, differentiation and function of the prostate [Abrahamsson, 1999].
Decursin has been recently identified as a novel therapeutic agent having potent anti-androgen
activities [Guo et al., 2007]. Hormonal therapy also slows the spreading of cancerous cells to
4

other parts of the body. In the most severe form of prostate cancer, M+, where cancerous cells
become hormone resistant, there is currently no cure.

Nonetheless, administration of

chemotherapeutic agents such as docetaxel combined with a bisphosphonate can be effective in
extending life and reducing pain [Westendorf and Hoeppner, 2007]. However, these powerful
toxic drugs eliminate both cancer cells and healthy cells. Herein lies one of the major issues that
challenges prostate cancer treatment; the absence of reliable markers [Pu et al., 2005]. Thus, the
need to identify molecular targets specifically involved in the growth and spread of cancer cells
is urgent.
1.4 Molecular Biology of Prostate Cancer
Cancer is a group of more than 200 diseases, thus the causes of cancer are complex and in many
cases unknown. The disease is initiated by mutations caused by carcinogenic agents that exert
their effect by either direct interaction with DNA or by indirect epigenetic events that modulate
gene expression without directly reacting with the base sequence of DNA [Ruddon, 1995].
Carcinogenic agents are generally classified as either chemical, biological, genetic, or radiation
[Pitot and Dragan, 1991]. They modify DNA sequences that code for proteins that either
increases the malignancy of a tumor cell or increases the chance that a normal cell develops into
a tumor cell [Osborne et al., 2004]. These mutated DNA sequences termed oncogenes, may
manifest

as

transcription

factors,

growth

factors,

regulatory

GTPases,

cytoplasmic

serine/threonine kinases, or cytoplasmic tyrosine kinases [Robert G. McKinnell, 2006].

In

contrast, tumor suppressor genes code for proteins that have a repressive effect on regulation of
the cell cycle or promote apoptosis.

5

1.4.1 Cell Cycle Regulation in Prostate Cancer
Cancerous cells are capable of going through unlimited number of cell divisions without any
signs of senesence. In mammalian cells, cell cycle progression is tightly regulated through the
activity of cyclin dependant kinases (CDKs) [Sherr, 1996]. CDKs are stage specific kinases that
allow transition of cells from one stage to the next. Alteration of the activity and expression
level of CDKs results in proliferation of cancer cells [Hashimoto et al., 2006]. The cell cycle is
also controlled by checkpoints that detect errors in DNA replication and chromosome
segregation.

Concomittant with excess cell proliferation, cancerous cells lose sensitivity to

signals for adherence, differentiation or death [Collins et al., 1997]. Cyclin D1 and its binding
partners (CDK4 and CDK6) are important regulators of G1 to S phase progression. In prostate
cancer, Cyclin D1 positively influences tumor growth by aberrant regulation of

androgen

receptor [Burd et al., 2006]. Similarly, Cdc6, a cell cycle regulatory gene involved in formation
of pre-replication complex is down regulated in prostate cancer [Robles et al., 2002].
1.4.2 Growth Factors Common to Prostate Cancer
The ability of cancer cells to promote cell proliferation, inhibit apoptosis and induce
angiogenesis is a reflection of the upregulation of certain oncogenic signaling pathways
[McCarty, 2004]. Biochemically, misregulation of growth factors and their respective signaling
pathways is associated with prostate cancer progression [Reynolds and Kyprianou, 2006].
Specifically,EGF/EGFR signaling pathway is over active in advanced prostate cancer [Culig et
al., 1994]. Inhibition of EGFR tyrosine kinase casused apoptotic death of metastatic prostate
cancer cell lines LNCap, DU145, and PC3 [Mimeault et al., 2007a].

EGF treatment also

increased androgen dependant AR transactivation in the recurrent prostate cancer cell line CWR6

RI [Gregory et al., 2004]. Administration of the antiandrogen bicalutamide combined with the
antiestrogen tamoxifen reduces the synthesis of IGF-I in prostate cancer cells [Boccardo et al.,
2006]. In addition, recent studies showed that in DU145 prostate cancer cells, IGF-I induced
EGFR transactivation leading to mitogenic activity [Zhou et al., 2006]. TGF-β suppresses
growth in normal cells, however in aggressive tumor cells it actively participates in angiogenesis
and extracellular matrix deposition [Pinkas and Teicher, 2006].
1.4.3 Malfunctioning Genes in Prostate Tumors
Tumor Suppressor Genes
The p53 protein is the most commonly mutated tumor suppressor gene associated with human
cancers [Harvey Lodish, 2000]. In normal cells, p53 causes arrest in G1/G2 phase in response to
DNA damaged caused by γ-irradiation. Cells lacking functional p53 are allowed to continue
cycling in the presence of damaged DNA. Mutations in p53 mainly occur in late stage prostate
cancer in association with androgen independence and metastasis, but also occur in
approximately 30% of early prostate cancer [SD Downing MSc, 2000]. Furthermore, restoration
of wild type p53 by electroporation into PC3 cell xenografts markedly suppressed tumor growth
compared to xenografts transfected with mutant p53 [Mikata et al., 2002].
PTEN, was the first phosphatase identified as a tumor suppressor gene. It has the ability
to remove phosphate groups attached to serine, threonine and tyrosine residues. In prostate
cancer, PTEN is inactivated by a combination of mechanisms including hemizygous deletion,
homozygous deletion, point mutations and promoter methylation [Isaacs and Kainu, 2001]. Wu
et

al

demonstrated

that

in

prostate

cancer

cells

with

inactivated

PTEN,

the

AKT/phosphoinositide-3 kinase pathway was constitutively activated due to increased
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accumulation of PTEN substrate PIP3 [Wu et al., 1998]. Activation of this pathway resulted in
suppression of apoptosis and increased cell survival. Mutations in PTEN are usually seen in
advanced prostate cancer and may play a role in acquisition of metastatic potential.
Oncogenes
Proto-oncogenes are normal genes that regulate cell growth and differentiation and become
tumor inducing upon activation. Activation can be accomplished by mutations that cause a
change in protein structure resulting in increased protein activity or concentration. In prostate
cancer, the c-myc oncogene has an important role in regulation of cellular proliferation,
differentiation and apoptosis [Grandori et al., 2000]. Overexpression and amplification of c-myc
gene is more prevalent in recurrent tumors and metastatic lesions than primary tumors [Buttyan
et al., 1987]. Recent studies demonstrated that down regulation of the c-myc gene resulted in
growth inhibition and apoptosis in prostate cancer cell lines [Napoli et al., 2006].
The Rho GTPases belong to the Ras superfamily of small GTP binding proteins that act
as molecular switches involved in cell motility and invasion, cytoskeleton organization and
signal transduction [Yao et al., 2006]. RhoC GTPase is over expressed in aggressive cancers and
is required for prostate cancer cell invasion [Gioeli, 2005].
The best characterized members of the Rho subfamily, RhoA, Rac1 and Cdc42 play
important roles in cellular proliferation, transformation and cell cycle progression [Adnane et al.,
1998]. Ghosh et al have shown that RhoA participates in signaling pathways controlling prostate
epithelial cell proliferation in a cell line derived from transgenic mice with prostate
adenocarcinoma [Ghosh et al., 2002]. In addition, high levels of Rac1 activity has been shown to
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suppress the expression of cyclin dependant kinase inhibitor p21 and promote uncontrolled cell
growth in prostate cancer cell lines [Knight-Krajewski et al., 2004].
Aurora kinases, another familiy of serine/threoninethat are involved in cell cycle
progression from G2 phase to mitosis.

Aurora kinase A is involved in coordination of

microtubule organizing center and Aurora kinase B functions in attachment of mitotic spindle to
the centromere. All three members (Aurora-A/B/C) of this gene family were reported to be over
expressed in many human cancers [Katayama et al., 2003]. Deregulation of Aurora kinase A/B
induces aberrant mitosis leading to chromosomal instability and centrosomal irregularity [Lee et
al., 2006]. Absence of regulated cell division eventually induces anueploidy, which is a driving
force in malignant progression [Ewart-Toland et al., 2005]. Recent studies show that Aurora
kinase B expression in prostate tumors positively correlates with increased Gleason score
[Chieffi et al., 2006]. Over expression of Aurora kinase A is noted in most high grade prostatic
intraepithelial neoplasia lesions [Buschhorn et al., 2005]
1.4.4 Role of Androgen
The growth, development, differentiation and maintenance of the prostate gland relies on the
production of androgens, mainly in the form of testosterone [Lindzey et al., 1994]. Androgen
secretion from leydig cells is stimulated by leutinizing hormone which is released in response to
binding of gonadotropin releasing hormone to gonadotropes in the anterior pituitary [Grossmann
et al., 2001]. Androgens exert their effect through binding to androgen receptor (AR). AR is a
member of the steroid receptor superfamily and contains an N-terminal transcription activation
domain, a central DNA binding domain, and a C-terminal steroid binding domain [MacLean et
al., 1997]. Once testosterone enters the cell, 5α-reductase converts it to dihydrotestosterone
9

which has an higher affinity for AR [Denmeade et al., 1996]. Upon ligand binding, AR becomes
activated and binds promoter sequences (androgen response elements) that drive the transcription
of androgen responsive genes.
Initially, like the normal prostate, cancerous prostate relies on androgens for growth.
Thus, blocking the action of androgens causes tumor regression.

However many tumors

eventually begin to regrow independent of androgens. [Bhuiyan et al., 2006]. There are several
possible mechanisms by which prostate cancer cells become androgen independent. Mutations
in AR may allow it to bind ligands non-specifically and thus activate AR [Koivisto et al., 1998].
Similarly, mutations in hormone binding not only causes increased sensitivity to other hormones
but also may cause AR to be responsive to antiandrogens [Akimoto, 1998].

In addition,

androgen refractory prostate cancer cells may bypass AR signaling as a result of constitutive
action of regulatory molecules downstream of AR [Bonkhoff, 1998].

Comprehensive

understanding of the molecular mechanisms by which prostate cancer cells become androgen
independent is necessary in order to develop effective therapies for advanced prostate cancer.
1.4.5 Roles of Actin Cytoskeleton and Microtubules
Cell migration is characterized by changes in the actin cytoskeleton and is a critical component
of tumor cell invasion and metastasis. Altered distribution and activity of microtubules also
contribute to the cells’ ability to migrate and interact with neighboring cells. Reorganization of
the actin cytoskeleton is the primary mechanism for cell migration and is subject to microtubule
dependant activities [Yamazaki et al., 2005]. Recent studies indicate that microtubule influence
on actin cytoskeleton is mediated through substrate contact formation [Rodionov et al., 1993].
Rho family of small GTPases (RhoA, Rac1,Cdc42) regulate the dynamics of actin cytoskeleton
10

associated with cell shape and behavior [Zhuge and Xu, 2001]. These GTP binding proteins are
active when GTP bound and inactive when GDP bound. This activation status is regulated by
GTPase activating proteins (GAPs) and guanine nucleotide exchange factors (GEF).

Rho

activation induces assembly of stress fibers and focal adhesions, GTP bound Rac induces
peripheral actin accumulation and membrane ruffling and Cdc42 induces filipodia [Edwards et
al., 1999]. The highly invasive prostate cancer cell line PC3 display 3-fold higher expression of
RhoA compared to minimally invasive PC3 cells [Hodge et al., 2003]. Activated Rac1 and
Cdc42 facilitate pRb hyperphosphorylation which induces E2F responsive gene transcription
thereby allowing entry in S phase [Gjoerup et al., 1998]. An increase in these actin remodeling
events are characteristic of metastatic tumor cells in various types of cancer [Wittekind and Neid,
2005]. More recent studies show that the presence of lamellipodia (membrane ruffling)
positively correlates with cell motility and polarity in prostate cancer cell lines [Strock et al.,
2006]. In addition, EGFR signaling causes activation of Rac 1 and subsequent membrane
ruffling and lamellipodia formation [Malliri et al., 1998]. LIMK1 is a downstream effector
kinase of Rac1 and Cdc42 that is directly involved in actin reorganization.

Furthermore,

increased activity of LIMK1 enhances cell spreading, cell migration and lamellipodia formation
Misra et al., 2005].
1.5 Angiogenesis and Metastasis
Solid tumors eventually stimulate outgrowth of capillaries by which new blood vessels are
formed; a process known as angiogenesis. These blood vessels penetrate the tumor growth
supplying nutrients and oxygen and removing waste products [Varner, 2006]. This process is
actually initiated by release of growth factors by tumor cells that signal the surrounding normal
11

host tissue to make proteins that stimulate growth of new blood vessels [Montesano et al., 1993].
This event marks the beginning of the transition of the tumor to a malignant state. Tumor cells
metastasize by invading blood vessels or lymphatic channels where they are free to seed out onto
tissue surfaces and develop secondary tumors. This is the most deadly aspect of cancer. In this
process a tumor cell has to detach from the primary tumor and from the extracellular matrix
(ECM). Many cell adhesion proteins such as E-cadherin are missing or compromised in tumor
cells [Sato et al., 1999]. This helps the cell to escape adhesion to other cells and allows it to
move more freely. During metastasis, tumor cells degrade the basement membrane in order to
disperse into the circulatory system [Yee and Shiu, 1986].

Penetration of the basement

membrane is accomplished through the action of degradative enzymes that may be secreted by
the tumor cells themselves. The steps involved in initiation, angiogenesis and metastasis are
illustrated in Figure 3.
1.5.1 Matrix Metalloproteinases
Matrix metalloproteinase’s are a family of at least 26 enzymes, 15 of which contain zinc in their
active site [Visse and Nagase, 2003]. There are two classes of MMPs, secreted proteins and
membrane bound proteins.

Soluble MMPs are secreted into the extracellular space upon

activation. Similarly, membrane bound MMPs become inserted into the plasma membrane when
activated. Nonetheless, most MMPs are characterized by a regulatory pro-domain, a catalytic
domain, a linker region and a hemopoexin domain [Hideaki Nagase, 2004].(Figure 4). MMPs
are primarily involved in the turnover of the ECM.

They also have roles in embryonic

development, tissue remodeling, wound healing and angiogenesis [Giambernardi et al., 1998].
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Figure 3 Stages in the Development of a Tumor. Outline of the process of tumor initiation and
acquisition of metatastasis
Nelson, et al., 2000
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propeptide
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C-terminal domain

Collagen like domain

C-terminal domain

C-terminal domain

Transmembrane

Cytoplasmic domain

Fibronectin type II

Figure 4 Stucture of Matrix metalloproteinases
72kD Pro-MMP-2, 92kD, Pro-MMP-9, 66kD Pro-MT1-MMP. Upon activation, the signal peptide and pro domain becomes cleaved
exposing the active site of the enzyme. Signal peptide (purple), propeptide/regulatory prodomain (gray), hemopoexin domain (red),
fibronectin domain (blue). Catalytic domains are represented by double arrows.
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Membrane-type MMPs are anchored to the membrane by a transmembrane domain or by GPI
anchored proteins. Activity of MMPs is regulated by a family of four endogenous inhibitors
TIMP 1-4 [Blavier et al., 2006]. Extracellular matrix metalloproteinase inducer (EMMPRIN)
plays a role in activation of MMPs and correlates with tumor progression [Ueda et al., 2007].
This family of proteolytic enzymes are collectively capable of degrading all components of the
ECM and are therefore major implicators of tumor cell invasion in a variety of cancers [Karadag
et al., 2004].
1.5.2 Membrane Type I Matrix Metalloproteinase
Membrane type 1 matrix metalloprotease also called MMP-14, is anchored to the plasma
membrane through its transmembrane domain such that the catalytic domain is exposed on the
surface of the cell [Nagakawa et al., 2000]. Activation of MMP-14 requires removal of the propeptide by a member of the proprotein convertase family, furin, resulting in a 57kDa active
enzyme [Yana and Weiss, 2000]. Once cleaved, MMP-14 is inserted into the plasma membrane
where TIMP-2 binds to its N terminus and it associates with a neighboring MMP-14 protein to
activate matrix metalloproteinase 2. Substrates for MMP-14 include, collagens I-III, fibronectin,
laminin-1, vitronectin, dermatan sulfate proteoglycan, proMMP-2 and proMMP13. The known
steps of the activation mechanism of MT1-MMP are outlined in figure 5a.

Expression of MT1-MMP is strongly associated with tumor progression and metastasis in almost
all cancers [Hofmann et al., 2000]. Sounni et al showed that over expression of MT1-MMP
promotes tumor growth and angiogenesis in breast cancer cells [Sounni et al., 2002]. Elevated
levels of MT1-MMP were shown to facilitate tumor progression and increase the growth of
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Figure 5 Activation mechanisms of MMPs
A: Pro-MMP-2 and Pro-MT1-MMP activation mechanism. Upon cleavage by furin convertases inside the cell, the
pro-peptide regulatory domain of MT1-MMP is cleaved. Next the MT1-MMP is inserted into the plasma membrane
with the catalytic domain exposed to the extra cellular space. Activation of pro-MMP-2 by MT1-MMP is assisted
by binding to a TIMP-2/MT1-MMP complex, which presents pro-MMP-2 to an adjacent active MT1-MMP. B:
Activation of Pro-MMP-9. Tissue inhibitor of matrix metalloprotease 1 (TIMP-1) binds to and inhibits pro-MMP-9.
In the absence of TIMP-1, MMP-3 readily activates pro-MMP-9. Formation of the ternary complex TIMP-1/MMP3/pro-MMP-9 causes the interaction between pro-MMP 9 and TIMP1 to be weakened. ProMMP 9 partially
dissociates from the complex and can be readily activated by free MMP-3.

16

malignant melanoma in vivo[Iida et al., 2004]. With its catalytic domain exposed to the ECM
environment, MT1-MMP is especially important in pericellular proteolysis. In prostate cancer,
MT1-MMP has been shown to correlate with tumor stage and promote metastasis of prostate
cancer cells to the lymph node and lung [Cao et al., 2005].

MMP-14 degrades several

components of the ECM; this degradative activity is enhanced by activation of latent MMP-2 and
MMP-9. Hence MT1-MMP is the most important proteinase involved in cancer cell migration,
invasion, and metastasis.

1.5.3 Matrix Meatlloproteinase-2/9
Matrix metalloprotease-2 and matrix metalloprotease-9 also termed gelatinase A and gelatinase
B respectively, are members of the matrixin family that are secreted into the extracellular space.
Like most MMPs, gelatinases are characterized by a signal peptide, a propeptide, and a catalytic
domain. Gelatinases have an additional fibronectin type II domain and gelatinase B has a unique
collagen like domain (Figure 4). Gelatins, collagen IV and V, aggrecan, elastin, and vitronectin
are substrates common to both gelatinases [Kherif et al., 1998]. Collagen I, VII, X, and XI,
tenascin C and β-amyloid protein precursor are substrates unique to Gelatinase A. Likewise,
collagen XIV is an additional MMP-9 substrate. However, recent studies have identified Ym1
and S100 proteins as substrates for MMP-2, MMP-9 or both [Greenlee et al., 2006]. These novel
substrates have key roles to play in the response to parasitic infections [Hung et al., 2002] and
inflammation [Eue et al., 2002]. Although MMP-2 and MMP-9 have been implicated in tumor
cell invasion in a variety of cancers, their role in prostate cancer is poorly defined. Activation of
17

MMP-2 occurs at the plasma membrane and is mediated by MMP-14 and TIMP-2 [HernandezBarrantes et al., 2000]. Active MMP-3 cleaves and activates proMMP-9, however a number of
proteolytic enzymes are capable of activating MMP-9 in vitro [Ramos-DeSimone et al., 1999].
The matrixin family of ECM degrading enzymes are capable of increasing their proteolytic effect
by activating each other and substrate overlap. The known steps of MMP-2, MMP-9 and MMP14 activation are depicted in (Figure 5b).
Enhanced expression of MMPs has been correlated with increasing malignancy
[Golubkov et al., 2005]. Nagakawa et al have shown that there is increased expression of MMP14 in androgen independent and invasive prostatic cancer cell lines [Nagakawa et al., 2000]. In
addition, MMP2 expression has been shown to be involved in the process of prostate cancer
invasion and metastasis [Liao et al., 2003]. Further, increased activity of MMP-9 in prostate
cancer cells has been correlated with tumor cell metastasis [Wilson et al., 2004].
1.6 LIM Kinase 1
LIM kinases and testes specific protein kinase (TESK) are subfamilies of LISK kinases, each
with two family members; LIMK1/2 and TESK1/2 respectively.

LISK kinases are

morphogenesis kinases that stabilize the structure of actin cytoskeleton through phosphorylation
and inactivation of cofilin [Manning et al., 2002]. LIMK1 is a dual specificity serine/threonine
and tyrosine kinase that has two zinc finger motif LIM domains, a PDZ domain, and a kinase
domain (Figure 6). Within the PDZ domain there are two nuclear export signal and within the
kinase domain there is a nuclear localization signal [Yang and Mizuno, 1999]. LIM kinases are
predominantly expressed in the brain and neural tissue [Yang et al., 2004]. There is substantial
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Figure 6 Structure of LIMK1
LIMK1 contains four domains, two consecutive LIM domains, a PDZ domain and a kinase
domain. Within the PDZ doamain two nuclear export signals are present. Within the kinase
domain there is a nuclear localization signal.
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evidence identifying LIMK1 gene deletion as a cause for development of cognitive disorder
observed in patients with Williams Syndrome [Hoogenraad et al., 2004].

1.6.1 Regulation and Function of LIMK 1
LIMK1 activity influences actin reorganization by regulating the activation status of actin
depolymerization factor cofilin. Upon phosphorylation by LIMK1, cofilin is unable to induce
globular actin (G-actin) formation. In eukaryotic cells, cofilin binds to filamentous actin (Factin) causing a conformational change in the actin subunits resulting in severing of F-actin to Gactin. Cofilin bound globular actin then associates with ADF-profilin, which causes cofilin/Gactin dissociation and promotes actin polymerization [Moriyama et al., 1996]. This cycle of
actin polymerization and depolymerization is continuous. LIMK1 inactivates cofilin by
phosphorylation on serine 3 residue [Toshima et al., 2001]. Thus inactive cofilin cannot sever
actin polymers and there is an accumulation of filamentous actin in the cell. Further, increased
activity of LIMK1 causes actin remodeling events that may induce formation of lamellipodia,
filipodia and stress fibers. Activity of LIMK1 is regulated through the Rho subfamily of small
GTPases [Lou et al., 2001]. Stimulation of EGF receptor signaling pathway has been shown to
activate Rho GTPases [Nogami et al., 2003]. GTP bound Rac 1, a member of this subfamily,
binds to PAK (p-21 activated kinase) homodimers at the N-terminus regulatory domain [Parrini
et al., 2002]. Binding of Rac 1 or its family member Cdc42, causes release of PAK’s auto
inhibitory domain from the kinase domain, resulting in cross phosphorylation and activation of
PAK1/PAK4 which can, in turn, activate LIMK1[Stofega et al., 2004]. Activation of LIMK1 by
Rac1 and Cdc42 mediated by PAK causes the formation of lamellipodia and filipodia
20

respectively. Inactive LIMK1 is maintained in “closed” conformation with LIM domains
associated with the kinase domain (Figure 7). Upon phosphorylation at T508, LIM domains of
LIMK1 dissociate from the C-terminal and the kinase domain is available for substrate
phosphorylation. LIMK1 inactivates cofilin. As a result cofilin is unable to bind to and induce
severing of filamentous actin. Panel C: Dephosphorylation of cofilin by slingshot restores it’s
activity. Cofilin can then bind to F-actin causing dissociation of actin subunits and formation of
G-actin. Binding of ADF-profilin frees cofilin from G-actin.
In its active conformation the N-terminus LIM domains of LIMK1 are accessible. Active
LIMK1 functions to inhibit the actin depolymerzing factor cofilin as mentioned above. LIMK1
can also be activated by a third Rho subfamily member RhoA. In this pathway, RhoA stimulates
Rho-associated serine/threonine kinase (ROCK) which in turn phosphorylates and activates
LIMK1 [Lin et al., 2003]. ROCK mediated activation of LIMK1 induces stress fiber formation.
In addition, bone morphogenic protein type II receptor (BMPR-II) negatively regulates LIMK1
through binding of the tail domain [Foletta et al., 2003]. The signaling mechanism underlying
cytoskeletal changes directed by LIMK1 is depicted (Figure 7). In addition, recent studies show
that

LIMK

forms

homodimer;

an

interaction

promoted

by

Hsp90

resulting

in

transphosphorylation and increased stability [Li et al., 2006].
1.6.2 Role of LIMK 1 in Cancer Progression
In order for tumor cells to become metastatic they must detach from neighboring cells and
degrade the extracellular matrix.

Both of these events require reorganization of the actin

cytoskeleton. Through the activity of LIMK1 there is reorganization of the actin cytoskeleton
that coordinates the formation of lamellipodia and filipodia; structures which enhances cell
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Figure 7 Activation and function of LIMK1
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Panel A: GTP bound Cdc42 and Rac1 bind to PAK1 homodimers resulting in dissociation and
transphosphorylation of PAK1. Active PAK1 phosphorylates LIMK1 at T508, causing a
conformational change in LIMK1 where kinase domain is available for substrate binding and
LIM domains accessible for interacting partners. Panel B: Phosphorylation of cofilin at Ser3 by
LIMK1 inactivates cofilin. As a result cofilin is unable to bind to and induce severing of
filamentous actin. Panel C: Dephosphorylation of cofilin by slingshot restores it’s activity.
Cofilin can then bind to F-actin causing dissociation of actin subunits and formation of G-actin.
Binding of ADF-profilin frees cofilin from G-actin.
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migration by projecting the leading edge of the cell [Small et al., 1999]. Davila et al have shown
that partial reduction in LIMK1 abolished invasiveness of the metastatic prostate cancer cell line
PC3 [Davila et al., 2003]. In addition, ectopic expression of LIMK1 promoted acquisition of
invasiveness in benign prostate epithelial cells. Introduction of a dominant negative mutant of
LIMK1 in breast cancer cells decreased motility and metastatic lesions in animals [Yoshioka et
al., 2003]. In fact, LIMK1 has been implicated in breast tumor cell growth, angiogenesis and
invasion [Bagheri-Yarmand et al., 2006]. Taken together, current findings implicate LIMK 1 as
a putative oncogene in prostate cancer.
1.6.3 LIMK1 in Cell Cycle Regulation
LIMK1/2 regulate actin cytoskeletal reorganization through phosphorylation of cofilin. Because
actin reorganization is a key event in mitosis and cytokinesis, LIMK1 has been implicated in cell
cycle progression. Reduction of LIMK1 alters cell proliferation in prostate cancer cells by
arresting cells in G2/M. In addition, during prometaphase and metaphase LIMK1 becomes
hyperphosphorylated and then returns to basal level as cells enter telophase [Amano et al., 2002].
This phenomenon is evident in both normal breast cells (HUMEC) and metastatic breast cancer
cells (MDAMB231), Figure 8. Sumi et al have also shown that LIMK1 activity is low during
interphase and peaks during mitosis [Sumi et al., 2002]. Moreover LIMK1 has been shown to
interact with 14-3-3ζ and p57Kip2, proteins involved in cell cycle check point control and
regulation of CDKs, respectively [Yokoo et al., 2003], [Peng et al., 1997].
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Figure 8 Gamma tubulin co-localizes with phospho-LIMK1 to the centrosome during mitosis
Panel A: Metastatic breast cancer cells stained with p-LIMK1 (red, arrow) and γ-tubulin (green, arrow) showed colocalization to centrosome (merged image). Panel B: During interphase p-LIMK1 staining was abolished. γ-tubulin
remained localized to the centrosome (green, arrow). Panel C: Co-localization of γ-tubulin and p-LIMK1 to the
centrosome is also evident in normal breat epithelial cells (HUMEC).
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1.7 Research Done in this Laboratory
Studies from our laboratory showed that ectopic expression of LIM kinase 1 is required for
prostate epithelial cell invasion. Over expression of LIMK1 was also observed in prostate tumors
and prostate cancer cell lines. Our previous works showed that reduced expression of LIMK1
resulted in G2/M arrest in metastatic prostate cancer cell lines. In addition, ectopic expression of
LIMK1 promoted invasiveness in benign prostate epithelial cells.

Our studies also

revealed that the level of phosphorylated cofilin remained unchanged upon reduction of LIMK1
expression. Immunofluorescence analysis showed localization of MT1-MMP to lamellipodia
structures and perinuclear region of PC3 cells.
However, antisense RNA mediated reduction of LIMK1 in these cells reduced the
accumulation of MT1-MMP at the cell periphery.

HYPOTHESIS: We speculate that LIMK1 induced invasion in prostate epithelial cells is
possibly occurring independent of cofilin inactivation and may involve members of MMP family
of ECM degrading enzymes.
1.8 Aims of Research
In this study, we attempted to elucidate the roles of LIM domains and the kinase domain of
LIMK1 in the invasion process and determine whether matrix metalloproteinaese are involved in
LIMK1 induced invasion of BPH cells. We have also attempted to determine any possible
association between LIMK1 and γ-tubulin as LIMK1 is localized to the centrosomes during early
phases of mitosis (unpublished observation).
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Experimental Design:
Cloning of constitutively active LIMK1, kinase dead LIMK1 and only the kinase domain of
LIMK1 in a mammalian expression vector
Generation of stable cell lines and selection of clones that express maximum amounts of LIMK1
by western blot analysis
Invitro invasion assays of transfected cells expressing different domains of LIMK1
Flow cytometric analysis to study the cell surface expression and activation of MT1-MMP in
transfected sublines
Gelatinase zymography was used to evaluate secretion of soluble MMP-2 and MMP-9 by
transfected cell lines
Invitro invasion assays utilizing inhibitors against MMPs to confirm their roles in LIMK1
mediated invasion
Immunoflourescence staining to visualize subcellular distribution of LIMK1 and it’s colocalization with MT1-MMP
Immunoprecipitation reactions with γ-tubulin were done in order to substantiate a role of LIMK1
in mitotic processes
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2: MATERIALS AND METHODS
2.1 Cell Culture
Benign prostate hyperplasia (BPH) cells were used as the model cell line to study the function of
LIMK1, as these cells express low levels of the LIMK1. BPH cells are immortalized luminal
epithelial cells originally obtained from a 68 year old male diagnosed with BPH [Hayward et al.,
1995]. BPH cells were maintained in high glucose containing DMEM (pH 7.1) (Invitrogen),
supplemented with 10% heat inactivated fetal bovine serum 1% antibiotic/antimycotic and 1%
glutamine at 37◦C humidified incubator with 5% CO2 and 95% air. Routinely, cells were
subcultured by trypsinization. To detach the cells, the monolayer was washed with 1X PBS
(Table 1), incubated with 5mL/100mm dish of 1X trypsin (Table 1) at room temperature for 5
minutes. Next, the trypsin was poured off and the dish was incubated at 37◦C for approximately
10 minutes. Detached cells were resuspended in complete medium and plated at 1:5 split.
Counfluency is usually attained within 48 hours.
The human caucasian breast cancer cells MDA-MB-231 were also maintained in high
glucose containing DMEM (pH 7.1) (Gibco), supplemented with 10% non-heat inactivated
serum, 1% antibiotic/antimycotic and 1% penicillin streptomycin. To detach the cells, the
monolayer was washed with 1X PBS (Table 1), incubated with 2mL/100mm dish of 1X trypsin
(Table 1)at 37◦C for 2 minutes. Detached cells were resuspended in complete medium and
plated at 1:5 split. Counfluency is usually attained within 48 hours. Both BPH and MDA-MB231 cells were harvested by resuspending trypsinized
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Table 1 Composition of buffers used
Name of Buffer
Lysis Buffer

Application
Protein extraction

Transfer Buffer

Western blot

Running Buffer
Blocking Buffer

SDS-PAGE
Western blot

Tris buffered saline
Tris buffered salinetween 20
4X sample buffer

Western blot
Western blot

4X non-reducing
sample buffer
Renaturing Buffer
Developing Buffer

Zymography

Staining Solution

Zymography

Destaining Solution
1X PBS
1X Trypsin

Zymography
Cell Culture
Cell Culture

10X MOPS buffer

RNA Gel preparation

Kinase Assay buffer

Kinase Assay

RIPA buffer

Immunoprecipitation

Composition
50mM Tris pH 8.0, 120mM NaCl, 2.5mM
EDTA, PMSF, 1mM Na3Vo4, 1%NP-40,
10ug/mL leupeptin/aprotinin, 50mM NaF,
40mM β-glycerophosphate
192mM glycine, 25mM Tris base, 20%
methanol
192mM glycine, 25mM Tris base, 0.1% SDS
5% milk, 137mM NaCl, 0.1% Tween, 20mM
Tris pH 7.6
137mM NaCl, 20mM Tris pH 7.6
137mM NaCl, 0.1% Tween, 20mM Tris
pH7.6
250mM Tris pH 6.8, 8%SDS, 40% glycerol,
20% β-mercaptoethanol
250mM Tris pH 6.8, 8%SDS, 40% glycerol,

Western blot

Zymography
Zymography

2.5% Triton X-100 in distilled water
50mM Tris pH 7.8, 0.2M NaCl, 5mM CaCl,
0.02% NP-40
0.5% w/v Coomasie blue R-250, 5% v/v
methanol, 10% v/v acetic acid
10% v/v methanol, 5% v/v acetic acid
50mM NaPO4, 300mM NaCl, 10% glycerol
50mM NaPO4, 300mM NaCl, 10% glycerol,,
5mM imidazole
50mM NaPO4, 300mM NaCl, 10% glycerol,
150mM imidazole
50mM Hepes, 150mM NaCl, 5mM MgCl,
10mM NaF, 1mM Na3VO4, 5mM MnCl
1% NP-40, 50mM Tris pH 7.5, 2mM EDTA,
150mM NaCL
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cells in 1XPBS and precipitating at 500xg at 4◦C for 10 minutes. Cell pellets were washed with
5mL of 1XPBS and centrifuged again at 500xg at 4◦C for 10 minutes. Pellets were stored at -4◦C
until used for protein extraction.
2.2 Preparation of LIMK1 Constructs
A DNA fragment containing full-length coding sequence of LIMK1 (Figure 9) originally cloned
in pIND vector (Invitrogen) was used to amplify a 878bp fragment of LIMK1 ORF flanking the
stop codon using primers shown in table 2. The reverse primer was designed to obtain a mutated
stop codon and a XbaI restriction site. The PCR product was cloned in pGEM-T Easy vector
(Promega). In parallel, the 3X flag epitope of the p3XFLAG-CMV vector (Sigma E4901) was
amplified using primers containing XbaI and ClaI sites and cloned in pGEM-T Easy vector.
Next, LIMK1 fragment (878bp) was cloned in pGEMT Easy containing 3X Flag at the 3’ end.
Cloning was done by digesting both plasmids with SSTI and Xba I. Since SSTI restriction site is
present in the multiple cloning site of pGEM-T Easy, the digested product was used as an insert
for pGEM-T Easy plasmid containing 3X flag epitope. DNA sequence of the LIMK1 fragment
with mutated stop codon and 3X flag tag was confirmed by sequence analysis (this construct was
already prepared in the lab). Next, the LIMK1 fragment was sub-cloned into pIND vector
containing the full length LIMK1 sequence replacing the original 878bp sequence. This cloning
generated full-length LIMK1 coding sequence with 3X flag tag at the 3’ end. Full length LIMK1
with 3X flag fusion protein (Figure 10) was subsequently cloned into Sal I and Cla I site in
pRev-TRE mammalian expression vector driven by CMV promoter (Clontech).
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ATGAGGTTGA CGCTACTTTG TTGCACCTGG AGGGAAGAAC GTATGGGAGA GGAAGGAAGC GAGTTGCCCG

70

TGTGTGCAAG CTGCGGCCAG AGGATCTATG ATGGCCAGTA CCTCCAGGCC CTGAACGCGG ACTGGCACGC

140

AGACTGCTTC AGGTGTTGTG ACTGCAGTGC CTCCCTGTCG CACCAGTACT ATGAGAAGGA TGGGCAGCTC

210

TTCTGCAAGA AGGACTACTG GGCCCGCTAT GGCGAGTCCT GCCATGGGTG CTCTGAGCAA ATCACCAAGG

280

GACTGGTTAT GGTGGCTGGG GAGCTGAAGT ACCACCCCGA GTGTTTCATC TGCCTCACGT GTGGGACCTT

350

TATCGGTGAC GGGGACACCT ACACGCTGGT GGAGCACTCC AAGCTGTACT GCGGGCACTG CTACTACCAG

420

ACTGTGGTGA CCCCCGTCAT CGAGCAGATC CTGCCTGACT CCCCTGGCTC CCACCTGCCC CACACCGTCA

490

CCCTGGTGTC CATCCCAGCC TCATCTCATG GCAAGCGTGG ACTTTCAGTC TCCATTGACC CCCCGCACGG

560

CCCACCGGGC TGTGGCACCG AGCACTCACA CACCGTCCGC GTCCAGGGAG TGGATCCGGG CTGCATGAGC

630

CCAGATGTGA AGAATTCCAT CCACGTCGGA GACCGGATCT TGGAAATCAA TGGCACGCCC ATCCGAAATG

700

TGCCCCTGGA CGAGATTGAC CTGCTGATTC AGGAAACCAG CCGCCTGCTC CAGCTGACCC TCGAGCATGA

770

CCCTCACGAT ACACTGGGCC ACGGGCTGGG GCCTGAGACC AGCCCCCTGA GCTCTCCGGC TTATACTCCC

840

AGCGGGGAGG CGGGCAGCTC TGCCCGGCAG AAACCTGTCT TGAGGAGCTG CAGCATCGAC AGGTCTCCGG

910

GCGCTGGCTC ACTGGGCTCC CCGGCCTCCC AGCGCAAGGA CCTGGGTCGC TCTGAGTCCC TCCGCGTAGT

980

*

CTGCCGGCCA CACCGCATCT TCCGGCCGTC GGACCTCATC CACGGGGAGG TGCTGGGCAA GGGCTGCTTC 1050
GGCCAGGCTA TCAAGGTGAC ACACCGTGAG ACAGGTGAGG TGATGGTGAT GAAGGAGCTG ATCCGGTTCG 1120
ACGAGGAGAC CCAGAGGACG TTCCTCAAGG AGGTGAAGGT CATGCGATGC CTGGAACACC CCAACGTGCT 1190
CAAGTTCATC GGGGTGCTCT ACAAGGACAA GAGGCTCAAC TTCATCACTG AGTACATCAA GGGCGGCACG 1260

**

CTCCGGGGCA TCATCAAGAG CATGGACAGC CAGTACCCAT GGAGCCAGAG AGTGAGCTTT GCCAAGGACA 1330
TCGCATCAGG GATGGCCTAC CTCCACTCCA TGAACATCAT CCACCGAGAC CTCAACTCCC ACAACTGCCT 1400
GGTCCGCGAG AACAAGAATG TGGTGGTGGC TGACTTCGGG CTGGCGCGTC TCATGGTGGA CGAGAAGACT 1470
CAGCCTGAGG GCCTGCGGAG CCTCAAGAAG CCAGACCGCA AGAAGCGCTA CACCGTGGTG GGCAACCCCT 1540

***

ACTGGATGGC ACCTGAGATG ATCAACGGCC GCAGCTATGA TGAGAAGGTG GATGTGTTCT CCTTTGGGAT 1610
CGTCCTGTGC GAGATCATCG GGCGGGTGAA CGCAGACCCT GACTACCTGC CCCGCACCAT GGACTTTGGC 1680
CTCAACGTGC GAGGATTCCT GGACCGCTAC TGCCCCCCAA ACTGCCCCCC GAGCTTCTTC CCCATCACCG 1750
TGCGCTGTTG CGATCTGGAC CCCGAGAAGA GGCCATCCTT TGTGAAGCTG GAACACTGGC TGGAGACCCT 1820
CCGCATGCAC CTGGCCGGCC ACCTGCCACT GGGCCCACAG CTGGAGCAGC TGGACAGAGG TTTCTGGGAG 1890
ACCTACCGGC GCGGCGAGAG CGGACTGCCT GCCCACCCTG AGGTCCCCGA CGCACTGCAG ATATCGGTAC 1960
CAGTCGACTC TAGAGGATCC CGGGCTGACT ACAAAGACCA TGACGGTGAT TATAAAGATC ATGACATCGA 2030
CTACAAGGAT GACGATGACA AGTAGTGAAT CGAT

2064

****

Figure 9 LIMK1 coding sequence
LIM1domain (pink), LIM2 domain (green), PDZ domain (yellow), Kinase domain (teal).
Mutated stop codon (red) and extra bases (gray). Flag sequence and Cla I site (dark yellow,
turquiose). Primer binding site for amplification of kinase domain only (*,****). Primer
binding site for kinase dead mutant amplification (**,****). Primer binding site for
constitutively active mutant (***,****).
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Table 2 Primers used for generate LIMK1-3XFLAG fusion protein
A. PCR primers used for the generation of 878bp LIMK1 fragment with mutated stop codon. B. Primers used to amplify 3XFLAG
epitope .
Template

Forward primer

Reverse primer

LIMK1-pIND

RC147 GCTATGATGAGAAGGTGGATGTGT

RC258 CCTCTAGACTCGTCACTACTTGTC

p3XFLAG-CMV

RC257 CAGATATCCAGCGACTACAAAGAC

RC258 CCTCTAGACTCGTCACTACTTGTC
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MRLTLLCCTW REERMGEEGS ELPVCASCGQ RIYDGQYLQA LNADWHADCF RCCDCSASLS HQYYEKDGQL

70

FCKKDYWARY GESCHGCSEQ ITKGLVMVAG ELKYHPECFI CLTCGTFIGD GDTYTLVEHS KLYCGHCYYQ 140
TVVTPVIEQI LPDSPGSHLP HTVTLVSIPA SSHGKRGLSV SIDPPHGPPG CGTEHSHTVR VQGVDPGCMS 210
PDVKNSIHVG DRILEINGTP IRNVPLDEID LLIQETSRLL QLTLEHDPHD TLGHGLGPET SPLSSPAYTP 280
SGEAGSSARQ KPVLRSCSID RSPGAGSLGS PASQRKDLGR SESLRVVCRP HRIFRPSDLI HGEVLGKGCF 350
GQAIKVTHRE TGEVMVMKEL IRFDEETQRT FLKEVKVMRC LEHPNVLKFI GVLYKDKRLN FITEYIKGGT 420
LRGIIKSMDS QYPWSQRVSF AKDIASGMAY LHSMNIIHRD LNSHNCLVRE NKNVVVADFG LARLMVDEKT 490
QPEGLRSLKK PDRKKRYTVV GNPYWMAPEM INGRSYDEKV DVFSFGIVLC EIIGRVNADP DYLPRTMDFG 560
LNVRGFLDRY CPPNCPPSFF PITVRCCDLD PEKRPSFVKL EHWLETLRMH LAGHLPLGPQ LEQLDRGFWE 630
TYRRGESGLP AHPEVPDDYK DHDGDYKDHD GDYKDHDG

669

Figure 10 LIMK1 ORF amino acid sequence
Amino acid sequence of LIMK1 ORF. Pink: LIM domain 1. Yellow: LIM domain 2. Blue: PDZ domain. Red: Kinase domain. Black residues are linker
sequences. To generate constitutively active LIMK1, T508 (green) was removed and two gluatmic acid residues inserted. To generate kinase dead LIMK1 an
aspartic acid residue (green) within the kinase domain was replaced with alanine. Amino acid sequences for 3X Flag epitope are in bold (purple).
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2.2.1 Generation of LIMK1 Mutants
Constitutively active LIMK1 (BPHLCA) and kinase dead (BPHLKD) constructs were generated
using Strategene’s Quick Change Site Directed Mutagenesis kit (Figure 11). Procedures were
followed according to the manufacturers protocol.

Briefly, using wild type LIMK1 as a

template, two mutagenic primers (Table 3) were used for amplification with PCR conditions
mentioned in table 4. The PCR product was digested with Dpn1 and used for transformed of
XL1-Blue Super competent cells. Antibiotic resistant colonies were picked and DNA extracted
using the boiling mini prep method. The construct containing the kinase domain only was
generated by PCR amplification using primers flanking the kinase domain. The forward primer
was designed to introduce an initiation codon. Then the amplified product was cloned into Sal I
and Cla I sites in the pRev-TRE vector. Cloning of the LIMK1 fragments were initially verified
by restriction digestion. Finally, DNA sequences of all constructs were confirmed by sequence
analysis.
2.3 Generation of Stable Cell Lines
Plasmid DNA containing LIMK1 fragments or the empty vector DNA were purified
using Qiagen spin mini prep DNA purification kit.The day before transfection BPH cells (5X105)
were seeded into six well dishes in complete growth media. Five to seven micrograms of cDNA
were used for transfection using Lipofectamine Plus 2000. Next day, media were replaced with
warm OptiMEM (800uL) and cells were incubated for two hours at 37◦C. Plasmid DNA was
warmed to room temperature and mixed with lipofectamine diluted in OptiMEM (100uL).
Lipofectamine (12uL) Invitrogen).
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Figure 11 LIMK1 Constructs
To generate constitutively active LIMK1, threonine 508 was removed and two gluatmic acid
residues inserted. To generate kinase dead LIMK1 an aspartic acid 460 was mutated to alanine.
Both mutations are within the kinase domain of LIMK1.
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Table 3 Primers used for generation of LIMK1 mutants
Construct

Forward primer

Reverse primer

K

RC271 GTCGACATGCCTCACGATACACT

RC269 ATCGATTCACTACTTGTCAT

KD

RC300 CATCATCCACCGAGCCCTCAACTCCCAC

RC301
GTGGGAGTTGAGGGCTCGGTGGATGATG

CA

RC294

RC295

CAAGAAGCGCTACGAAGAGGTGGTCGGCAAC

GTTGCCCACCACCTCTTCGTAGCGCTTCTTG

Table 4 PCR Conditions for LIMK1 Mutagenesis
To achieve multiple amino acid insertions and deletions, 18 cycles of amplication was necessary.
Cycles

Temperature

Time

1

95◦C

30s

18

95◦C

30s

55◦C

1min

68◦C

2min

36

DNA mixed with OptiMEM (100uL) was added to the mixture and incubated at room
temperature for 30 minutes. Next the DNA mixture was added to BPH cells containing 800uL of
OptiMEM. Transfected cells were incubated at 37◦ in a humidified CO2 incubator for 3 hours.
Next, one mL of complete growth media supplemented with 20% FBS was added to the cells and
incubation continued for 24hrs.
After 48-72hrs post transfection, cells were treated with hygrpmycin (8ul/ml-Invitrogen).
Antibitic resistant cells were cloned by incubating them with trypsin soaked cloning disc for 7-10
minutes at room temperature and transferring the disc into 24 well dish (1 disc/well). Cells were
maintained in complete growth media containing hygromycin and screened for transgene
expression as described below.
2.4 RNA Extraction
Total RNA was extracted from transfected cells using Promega total RNA extraction kit.
Approximately 1.5X106 cells were harvested and processed for RNA extraction according to the
manufacturers protocol.

Briefly, cell pellets were homogenized in denaturing solution by

vortexing vigourously. Then phenol chloroform was added to the suspension and samples were
incubated on ice for 15 minutes. Samples were then centrifuged for 20 minutes at 10000xg at
4◦C. After centrifugation, the aqueous layer was recovered and an equal volume of isopropanol
was added. Samples were then incubated at -20◦C for 18 hours to precipitate the RNA. The next
day 1mL of ice cold 70% ethanol was added to the solution and then centrifuged at 10000xg for
10 minutes at 4◦C. The resulting pellet was air dried for approximately 20 minutes and then
resuspended in nuclease free water. Total RNA concentration of each sample was determined in
a spectrophotometer at 260nm wavelength. Integrity of the RNA samples were determined by
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formaldehyde (3%) agarose gel (1%) electrophoresis in 1XMOPS buffer (Table 1).

RNA

samples were prepared for analysis by adding 15uL of RNA sample loading buffer (Sigma 4268)
to 5uL of RNA sample (5-7ug) and boiling as 65◦C for 15 minutes.
2.5 Reverse Transription PCR
Copy DNAs of the transgenes from LIMK1 expressing cell lines were amplified using stratagene
one step RT-PCR kit, according to the manufacturers protocol. Each reaction contained total
RNA sample (1ug), RNase free water, RT-PCR buffer, primers (20uM, Table 5), and dNTPs
(0.4mM each, provided with kit). Then samples were denatured at 65 ◦C.for 15 minutes and then
cooled to 37◦C for 3 minutes in thermocycler. Next, reverse transcriptase and DNA polymerase
were added to the reaction and samples were incubated for the specified time (Table 6) for
reverse transcription.
2.6 Preparation of Crude Protein Extracts
Fresh or frozen cell pellets were resuspended in protein extraction buffer (Table 1) with
inhibitors and then subjected to freezing and thawing for 6-7 cycles in a dry ice ethanol bath.
First suspended cells were frozen for approximately 1 min, thawed at 37◦C, and then vortexed
vigourously for 20-30 seconds. To ensure complete lysis, lysates were observed under the
microscope. Then lysates were centrifuged at 500xg for 15 minutes at 4◦C. The supernatants
were transferred to clean microfuge tubes and protein concentrations were measured using
Bradford assay (BioRad). A standard curve was generated using BSA (New England Biolabs) to
quantify the protein concentration.
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Table 5 Primers used in RT-PCR
Description of primers used in reverse transcriptase PCR. Amplification using Flag specific primer (RC269) confirmed
expression of LIMK1 transgene.
LIMK1 ORF

Forward Primer

Reverse Primer

Position 872, PDZ

RC145, TGGACGAGATTGACCTGCTGATTC

RC269, ATCGATTCACTACTTGTCAT

RC130, CAGGTGAGGTGATGGTGATGAAGG

RC269, ATCGATTCACTACTTGTCAT

domain
Position 1247,
kinase domain
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Table 6 RT-PCR Amplification Summary
Description of PCR conditions used in reverse transcriptase PCR.
Cycle

Temperature

Time

1

95◦C

1min

42◦ C

90min

95◦ C

30s

50◦ C

30s

68◦ C

4min

68◦ C

10min

40

1
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2.7 Western Blot Analysis
Fifty micrograms of total proteins in crude cell lysates were denatured in 1X sample buffer
(Table 1), boiled for 5 mins and separated by SDS-PAGE. Seperated proteins in the gels were
transferred to a polvinylidene fluoride membrane (Pall Corporation) at room temperature for
18hrs at 20v in transfer buffer (Table 1). Membranes were stained with India ink (1:1000) for 15
minutes at room temperature to visualize lanes. Next, membranes were incubated in blocking
buffer (5% milk TBS-T) for 90 minutes at room temperature. Proteins in the membrane were
detected by reacting with specific primary and secondary antibodies (Table 7) diluted in blocking
buffer (Table 1) for specified the time (Table 7). Membranes were washed extensively in
washing buffer (Table 1) and positive signals detected by chemiluminescence using a west femto
chemiluminescence HRP substrate detection kit from Pierce.
2.8 In vitro Invasion Assay
Treatment of Cells Prior to Seeding
To sensitize cells for treatment with epidermal growth factor, 60% confluent dishes were washed
with 1XPBS (Table 1) and incubated with phenol red free DMEM complete media supplemented
with *10% charcoal stripped fetal bovine serum (CSFBS) for 48 hours. Then the monolayer was
washed with 1XPBS and incubated with serum free phenol red free DMEM media for 24hrs.
(2.5 grams of charcoal was combined with .25 grams of dextran and q.s. to 1L in 1M tris and
stored at 4◦ o/n. The next day, the charcoal was autoclaved and combined with serum(1:1) ratio
and stirred for 1hr at 45◦. To remove charcoal the serum was centrifuged )
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Table 7 Antibodies Used in Protein Detection
Antibody
Flag (Sigma)
Gapdh
LIMK1 (Transduction laboratories)
Gamma tubulin (Sigma)
p-LIMK 1 (Abcam)
p-LIMK 2 (Abcam)
Bcl-2
Gamma tubulin (Sigma)
Flag (Sigma)
MT1-MMP (Neomarker)
Anti-mouse (Jackson Immunologicals)
Anti-rabbit (Jackson Immunologicals)
Cy 3 conjugated antimouse
Cy 5 conjugated antimouse
p-LIMK1 (Cell signaling)
Alpha tubulin
Flag (Sigma)
MT1-MMP (Chemicon)

Application
Western blot
Western blot
Western blot
Western blot
Western blot
Western blot
Immunoprecipitation
Immunoprecipitation
Immunofluorescence
Immunofluorescence
Western blot
Western blot
Immunofluorescence
Immunofluorescence
Immunofluorescence
Immunofluorescence
Immunoprecipitation
Flow cytometry
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Concentration
1:2000
1:500,000
1:100
1:5000
1:75
1:100
1ug/100ug lysate
1ug/100ug lysate
35ug/mL
1:250
1:30,000
1:20,000
1:200
1:200
1:50
1:2000
1ug/100ug lysate
5ug/million cells

Incubation
1hr @ RT
1hr @RT
O/N @ 4 ◦C
1hr @ RT
O/N @ 4 ◦C
O/N @ 4 ◦C
O/N @ 4 ◦C
O/N @ 4 ◦C
1hr @ RT
1hr @ RT
30 min @ RT
30 min @ RT
30 min @ RT
30 min @ RT
1hr @ RT
1hr @ RT
4hrs @ 4 ◦C
3hrs @ 4 ◦C

Invasion Assay
For the invasion assay, ECM fluorometric kit (ECM 554) from Chemicon was used. Experiment
was carried out according to the manufacturers protocol with some modifications. Cells were
seeded at a density of 1.25X105 in serum free media in matrigel coated inserts that had been
rehydrated for 30 minutes.

In addition, EGF was added to the cell suspension at a final

concentration of 10ng/mL. For inhibition studies, the matix metalloproteinase inhibitor GM6001
was added at a final concentration of 25uM. EGF (100nM) was added to the lower chamber as
the chemoattractant. Cells were incubated at 37◦C in a CO2 incubator for 48hrs. At the end of
incubation, media was removed from each insert and discarded. Inserts were transferred to clean
wells (24 well dish) containing 225uL of cell detachment buffer (provided with the kit) and
incubated at 37◦C in a CO2 incubator for 1 hour. During this incubation, samples were gently
rocked back and forth every 15 minutes to facilitate cell detachment. Also, cells that had
completely traversed the matrigel membrane to the bottom wells were counted. Next, 75uL of
lysis buffer/dye solution (provided with the kit) was added to each well and incubated at room
temperature for 15 minutes. Lysis buffer/dye solution with no cells was used as a blank. After
incubation, 200uL from each sample was transferred to a clean 96 well plate for fluorescence
measurement in a Wallac Victor 2 at 480/520 excitation/emission settings.
2.9 Gelatin Zymography
Transfected cells (2.5X105) cells were seeded into six well dishes and incubated for 24hrs. Next
day, media was replaced with phenol red free DMEM supplemented with 10% charcoal stripped
FBS and cells were incubated for at 37◦C in a CO2 incubator for 48hrs. Cells were then serum
starved for 24hr at 37◦C in a CO2 incubator. Next, cells were treated with EGF at a final
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concentration of 10ng/mL for 24hrs at 37◦C in a CO2 incubator.

After incubation, the

conditioned media was harvested and centrifuged at 500xg for 5minutes at 4◦C. Supernatant was
transferred to a clean microfuge tube and stored at -20◦ C. For analysis, 15uL of each sample
was incubated with 5uL of non-reducing loading buffer (Table 1) at room temperature for 15-20
minutes. Samples were then separated on a 10% SDS gel co-polymerized with 1mg/mL gelatin.
Gelatin was dissolved at 60◦C. for 20 minutes. Gels were run at 125v until the dye front ran off
the gel. For better separation, gels were run for an additional 10 minutes. Next, gels were
incubated in renaturing buffer (Table 1) for 30 minutes. Gels were washed twice and then
incubated in developing buffer (Table 1) for 30 minutes. At this point, the developing buffer was
decanted, fresh developing buffer was added and gels were incubated at 37◦C for 24hrs. Next
day, gels were stained in staining buffer (Table 1) until they became uniformly blue. To see
gelatinoic bands, gels were destained (Table 1) as needed. Once bands appeared, gels were
immediately dried for 3hrs. Bands were quantitated by densitometric analysis using Gene snap
software.
2.10 Quantitative Real-Time PCR
Total RNA extracts were obtained as described in section 2.3. For cDNA synthesis, BioRad
iScript kit was used according to manufacturer’s protocol. Briefly, RNase free water and 5X
reaction mix (provided with kit) were added to total RNA samples (1ug). Next, samples were
denatured at 65◦C for 15min, cooled to 37◦ C for 3 minutes in a thermocycler.

Reverse

transcription was carried out at 42◦C in thermocycler for 90min. Real-time PCR was performed
using a kit (Biorad SYBR green). This kit provided a 2X reaction mix to which primers,
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cNDA (6uL), and nuclease free water was added to a final volume of 25uL.A RT-PCR reaction
without revers transcriptase was used as a control. Primer sequences and PCR cycles are
indicated in tables 8 and 9, respectively.

Reactions were carried out in BioRad iCycler

thermocycler.
Calculation of Gene Expression
Quantification of the target gene was calculated using ∆Ct method and GAPDH as a reference
gene.
To calculate relative expression, the target gene expression was normalized for each sample:
2(CT(GAPDH)-CT(target gene)= Expression
Fold change expression was calculated as a ratio of expression of target gene in normal cell line
to expression of target gene in test cell line: Normal expression= ∆Ct normal cells/∆Ct normal
cells; Tumor expression=∆Ct tumor cells/ ∆Ct normal cells.

2.11 Flow Cytometry
Treatment of Cells Prior to Seeding
To sensitize cells for treatment with epidermal growth factor, 60% confluent cells were
incubated with phenol red free DMEM complete media supplemented with 10% charcoal
stripped fetal bovine serum for 48 hours. Next, cell monolayers were washed with 1XPBS
(Table 1) and incubated with serum free and phenol red free DMEM complete media for 24hrs.
At this point, EGF (10ng/mL) was added to each dish and cells were incubated for 24 hours.
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Table 8 Quantitative PCR amplification summary
Data was collected after each cycle of amplification.
Cycle

Temperature

Time

1

95◦C

30s

40

95◦C

30s

56◦C

30s
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Table 9 Primers used in Real Time PCR
Description of target sequences amplified in quantitative PCR.
Protein

Length

Forward primer

Reverse primer

GAPDH

85bp

ATGGCCTTCCGTGTTCCTAC

TGATGTCATCATACTTGGCAGG

MT1-MMP

295bp

GTCTCCTGCTCCCCCT

CGAACATTGGCCTTGATCTCA

MMP-2

501bp

GCAAGTTTCCGTTCCGCTTCC

CAGTACCAGTGTCAGTATCAGC
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MT1-MMP Surface Staining
EGF treated cells were harvested by incubating with 3ml/00mm dish of cell stripper (Cell Gro)
for 15-20 minutes. Two ml of PBS was added to each dish and cells were collected. Five X
10^5 cells were aliquoted into 5mL falcon tubes and centrifuged at 500xg for 10minutes. Cells
were resuspended in 1XPBS with 3%FBS containing MT1-MMP antibody (Chemicon) at a
concentration of 5ug/million cells. Cells were incubated at 4◦C with end over end rocking for
three hours. Next, cells were washed in PBS with 3% FBS and centrifuged at 500xg for 5
minutes. This step was repeated twice. Samples were incubated with the secondary antibody
conjugated with Alexa 488 (molecular probes) at a concentration of 1:800 for 30min at 4C◦ with
end over end rocking. Cells were washed next in 1XPBS with 3%FBS and centrifuged at 500xg
twice and resuspended in the fixation buffer (2% paraformaldehyde in 1XPBS). To prevent
clumping, pluronic solution (Sigma) was added to the cell suspension at a concentration of
100uL/mL. Prior to use, fixation buffer was autoclaved and filter sterilized. Samples were
stored at 4◦C until acquisition in a flow cytometer (FACS Calibur/BD Biosciences).
2.12 Dual label Immunofluorescence Analysis
Preparation of Polylysine Coated coated Coverslips
Coverslips were coated with 1% Poly-L-lysine diluted in sterile borate buffer (2mM EDTA,
89mM Tris/boric acid). First, coverslips (12mm diameter, Fisher) were sterilized in 85% ethanol
and allowed to air dry. Next, 200uL of 1Xpoly-L-lysine was added to each coverslip and
incubated for 10mins at room temperature. Poly-L-lysine was removed at the end of inubation
leaving behind a thin layer. Coverslips were allowed to air dry for approximately 30 minutes.
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Treatment of Cells Prior to Staining
Typically, 2X104 cells were seeded on poly-L-lysine coated 12mm diameter coverslips (Fisher)
in 24 well dishes and incubated overnight at 37◦C in a CO2 incubator. The next day or once cells
adhered, media was changed to phenol red free DMEM containing 10% charcoal stripped FBS
and incubation continued for 48hrs at 37◦C in a CO2 incubator. Next, cells were treated with
serum free media and incubated for another 24hrs. After 24hrs, cells were treated with EGF
(10ng/mL) in phenol red free DMEM media for 30 minutes at 37◦C in a CO2 incubator.
Immunostaining
Cells were washed in 0.1M phosphate buffer (3X), and fixed in freshly prepared 4%
paraformaldehyde in 0.1M phosphate buffer for 10mins. Cells were washed in 0.1M phosphate
buffer (3X) and permeabilized by incubating in 0.2% triton X100 for 10 minutes at room
temperature. Next, cells were washed with 0.2% tritonX100 in 0.1M phosphate buffer. At this
point, coverslips were removed from the culture dish and placed cell side up onto filter paper
covered with parafilm. Cells were subjected to blocking at room temperature in 10% goat
serum, 0.2% triton X100 in 0.1M phosphate buffer for 1.5 hour.

Primary and secondary

antibodies (Table 7) were diluted in blocking buffer and applied (75uL) to coverslips. Primary
antibodies were combined and applied to coverslips for 1hr.

Secondary antibodies were

centrifuged at 12000xg for 3 minutes prior to use. Coverslips were washed extensively with
0.1M phosphate buffer (six times for 5 minutes each). Cells were postfixed for 5 minutes and
then stained with phalloidin (Company 1:40) for 15 minutes at room temperature. Coverslips
were washed with 0.1M phosphate buffer (3X) and then mounted with biomedia gel mount
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(BioMeda). Mounted cells were stored in the dark for 18hrs. Flourescent cells were visualized
in a confocal microscope (Carl Ziess) at 60X oil objective. Images were also deconvoluted.
2.13 Preparation of Nuclear and Cytoplasmic Extracts
Nuclear extracts of MDA-MB-231 and BPH-LIMK were prepared using NE-PER kit (Pierce).
Briefly, ice cold cytoplasmic extraction reagent I was added to cell pellet and vortexed
vigorously for 15 seconds and incubated on ice for 10 minutes. Then cytoplasmic reagent II was
added to each suspension, vortexed for 5 seconds and incubated on ice for 1 minute. To collect
cytoplasmic extracts, samples were centrifuged at 16000g for 5 minutes. To obtain the nuclear
fraction, nuclear extraction buffer was added to the remaining pellet, vortexed for 15seconds
then incubated on ice for 10 minutes. The cycle of 15 second vortex and 10 minutes on ice was
repeated until 40 minutes elapsed. Sample were then spun down at 16000g for 10 minutes.
Protein concentrations were determined using Bradford assay (BioRad). Reagent dye (BioRad)
and BSA (New England Biolabs) were used in preparation of standards.
2.14 Immunoprecipitation
Cell lysates were prepared as described above in RIPA buffer (Table 1). Protein concentrations
were determined using Bradford assays. Typically, 1ug antibody per 100ug of protein was
incubated at 4◦C for 4 hours.

Next, 30uL of protein A/G sepahrose beads (Santa Cruz

Biotechnology) was added to the tube and incubated for 18 hours at 4◦C with end over end
rocking. Next day, samples were centrifuged at 100xg for 2 minutes at 4◦C. Supernatants were
removed and saved for analysis. Beads were washed three times 5 minutes each in 500uL of
RIPA buffer and centrifuged at 200xg for 5 minutes. To separate protein complexes and beads,
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16uL of distilled water and 5uL of 4X sample buffer were added to the beads, boiled for 5
minutes and separated by SDS-PAGE. Immunoprecipitated proteins were detected by western
blotting as described above.
2.14.1 Calf Intestinal Alkaline Phosphatase Treatment
Nuclear extracts (500ug) resuspended in modified RIPA buffer (1%nonidet P-40, 50mM Tris pH
8.5, 2mM EDTA, 150mM NaCL) were dephosphorylated by calf intestinal alkaline phosphatase
(CIAP/New England Biolab). Extracts were diluted in 1XCIAP buffer (550uL) and treated with
CIAP (5uL at 10U/uL) buffer. Extracts were incubated at 37◦C for 30 minutes and used for
immunoprecipitation as described in the previous section.
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3. RESULTS
3.1 Expression Analysis of LIM kinase 1 Transgene in Transfected BPH cells
To confirm that transfected cells were expressing LIMK1 transgene, total RNA extracts
containing mRNA of BPHLCA, BPHLKD and BPHLK cells were used for RT-PCR. RNA
concentration was determined by spectrophotometric analysis. RNA integrity was detected on a
formaldehyde (3%) agarose gel (1%) which showed intact 18S and 28S ribosomal RNA bands
(Figure 12). One microgram of each RNA sample was used for reverse transcriptase PCR
reaction. BPH cells expressing transgenes of LIMK1 (BPHLCA, BPHLKD), were amplified using
upstream PDZ domain primers and downstream Flag specific primers (Figure 12a). Each sample
yielded the expected band size of 1.3 kb as a result of LIMK1 transgene amplification. For
BHPLK mRNA an upstream kinase domain primer and downstream flag specific primer were
used which yielded a 1000bp cDNA fragment (Figure 13b).
Because phosphorylation at T508 activates LIMK1, we wanted to study the effect of
expression of active LIMK1 or kinase dead LIMK1. In addition, a cell line expressing only the
kinase domain of LIMK1 was generated in order to see whether LIM domains are essential for
the effect of LIMK1.

BPH cells expressinig constitutively active (BPHLCA), kinase dead

(BPHLKD) and kinase domain only (BPHLK), LIMK1 were generated by stable transfection as
mentioned before. BPHLCA was generated by replacing T508, where it is phosphorylated with
two glutamic acid residues. This mutation mimics phosphorylation by providing positive charge
and altering structural conformation (Figure 7).
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BPHV

BPHLK

BPHLCA

BPHLKD
28S rRNA

4kb

18S rRNA

2kb

Figure 12 Electrophoresis analysis of total RNA showing intact ribosomal RNA

A

1650b p

BPHLCA BPHLKD

1000bp

BPHLK
B

1000b p

850b p

Figure 13 Reverse transcription PCR
A: Amplicons of BPHLCA and BPHLKD Panel B: Amplicons of BPHLK. After RT-PCR, cDNAs
were analyzed by gel electrophoresis.
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In addition, this mutant of LIMK remains in the open conformation BPHLKD, was
generated by removal of an aspartic acid residue from the activation loop and replacing it with an
alanine residue. Mutation at this position has been shown to inhibit it’s kinase activity. [Rosso et
al., 2004].
To identify clones that had the highest expression level of the transgene, western blot
analysis was done using anti-Flag monoclonal antibody, (Figure 14). The housekeeping gene
GAPDH was used as a loading control.

Total protein was extracted from each cell line

expressing LIM kinase 1 mutants. These include BPHLCA (constitutively active), BPHLKD
(kinase dead), BPHLK (kinase domain only) and BPHLV (vector only). Immunoblot analysis
showed that all LIM kinase 1 mutants expressed Flag tags (Figure 14). Protein extracts were
also analyzed for LIMK1 expression, which showed that BPHL sublines expressing different
domains of LIMK1, express higher level of LIMK1 relative to untransfected BPH cells, and cells
transformed with the vector (Figure 15).
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BPHV

BPHLK

BPHLKD

BPHLCA
FLAG

75kD

37kD
GAPDH

Figure 14 Flag expression confirms integration of LIMK1 mutants in BPH cell chromosome.
Lane 1 vector, Lane 2 constitutively active LIMK1, Lane 3 kinase dead mutant, Lane 4 kinase
domain only mutant. Fifty microgram of protein was loaded and blot probed with anti Flag
1:2000 follwed by, anti-mouse-HRP 1:3X104antibodies.
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BPH

BPHV

BPHCA BPHKD BPHK

75kD

PC3

LIMK1

37kD

GAPDH

Figure 15 Expression analysis of LIMK1. BPH cells transfected with LIMK1 mutants
Lane 1:untransfected parental cell line, Lane 2: vector only cell line BPHV, Lane 3: constitutively
active mutant BPHLCA. Lane 4:kinase dead mutant, BPHLKD Lane 5:kinase domain only
mutant. Lane 6:PC3-prostate cancer cells which overexpress LIMK. Fifty microgram of total
protein loaded in each lane and blot probed with antiLIMK1 antibody at 1:100 dilution.
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3.2 Catalytically Inactive LIMK1 is Invasive
Previously, our lab has shown that a reduction in LIMK1 expression results in loss of
invasiveness in PC3 cells.

Also, ectopic expression of LIMK1 in BPH cells resulted in

acquisition of highly invasive phenotype. In this study, we wanted to determine which domains
of LIMK1 is essential for the invasive property of the protein. We used a flourormetric invasion
assay using BPH cells expressing LIMK1 mutants (BPHLCA, BPHLKD, BPHLK) or the vector
(BPHV). In order to stimulate the EGF signaling pathway, transfected cell lines were treated with
EGF (10ng/mL) for 24hrs prior to the assay. EGF signaling pathway stimulates Rho GTPases
activity in which LIMK1 is a downstream effector kinase. In addition, we used EGF (100nM) as
the chemoattractant for invasion assays of BPHL cell lines. Cells that invaded through the
matrigel were quantitated by fluorescence reading (Figure 16). Cells that traversed through the
matrigel and accumulated in the bottom chamber were counted (Figure 17).

The raw

fluorescence data showed that the cells expressing BPHLKD had the number of invaded cells
comparable to that of BPHLCA.

Transfected cell lines expressing BPHLK and BPHV had

comparable RFU values and were approximately equal to the RFU values of wells without any
cells. The cell count data indicated that BPHLCA cells had the highest percentage of invaded
cells compared to the control cells BPHV. For the BPHLKD, cell line the percentage of invaded
cells was similar to that of BPHLCA. BPHLK cells showed a reduced number of invaded cells.
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Figure 16 Invitro Invasion assays of EGF treated transfected BPH cells.
With EGF as an chemoattractant. Graphical representation of population of cells that penetrated
matrigel coated membranes. Values are mean +/- SE of three experiments. * P=0.820 **
P=0.045 and *** P=0.003 when compared to control (BPHV) cells.
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Figure 17 Percent of invasion of BPH-LIMK1 cell lines
Relative abundance of the invaded BPH cells BPHK, BPHKD, BPHCA, compared to BPHV cells.
Values are mean +/- SE of three experiments. * P=0.009, ** P=0.009, *** P=0.002 when
compared to control (BPHV) cells.
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3.3 LIMK 1 Induced Invasion is Mediated by Matrix metalloproteinases
To determine whether MMPs are involved in LIMK1 mediated invasion, we repeated the above
assay using GM6001, an inhibitor of matrix metalloproteinase -2 and -9 [Nelson et al., 2000].
The broad spectrum matrix metalloproteinase inhibitor is GM6001 is a synthetic polypeptide that
competively inhibits matrix metalloproteinases by occupying the substrate binding sites
[Boghaert et al., 1994]. Xue et al have shown that GM6001 specifically inhibits MMP-2 and
MMP-9 in cultured human keratinocytes as observed in in migration assays [Xue et al., 2004].
For invasion assays, cells were seeded with or without GM6001 (25uM) added to the media and
the assay was continued as mentioned previously.

Invaded cells were quantitated by

fluorescence measurement and cell counting as described above. RFU values showed that there
was a considerable decrease in invasion of BPHL cell lines expressing constitutively active or
kinase dead LIMK1 upon treatment with of MMP inhibitor GM6001 (Figure 18). BPHL cell
lines expressing constitutively active or kinase dead LIMK1 were equally inhibited. There was
no change in the invasiveness of BPHLK cells in fluorometric assays upon addition of GM6001.
However, the number of BPHLK cells that traversed the matrigel membrane were decreased in
the presence of GM6001 (Figure 19). The cell count values the showed a greater inhibition of
invasion in BPHLCA and BPHLK upon treatment with GM6001.

This result supports the

hypothesis that LIMK1 induced invasion is in part mediated by LIM domains.
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Figure 18 Inhibition of MMPs decreased invasion of BPH cell lines
Cell lines expressing different domains of LIMK1 were inhibited. Graphical representation of
population of cells that penetrated matrigel coated membranes. Values are mean +/- SE of three
experiments. MMPs inhibitor (GM6001) substantially reduced the ability of BPHLCA and
BPHLKD to invade matrigel coated membranes. BPH cells expressing only the kinase domain of
LIMK1 (BPHLK) were not inhibited by GM6001.
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Figure 19 MMP inhibitor GM6001 reduced the invasiveness of BPH cells expressing LIMK1
Transgenes with intact LIM domains. Graphical representation of population of cells that penetrated matrigel coated
membranes. Percentage of cells that traversed through the matrigel membrane and accumulated in the lower chamber. Values
are mean +/- SE of three experiments
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3.3.1 LIMK1 Expression Altered the Concentration of Secreted pro-MMP2 and proMMP9 and increased mRNA Concentration of MMP2
Subtrate Gel Analysis
To analyze any alteration in the expression of MMPs in BPH cells expressing LIMK 1 mutants,
we used gelatinase zymography. Matrix metalloproteinase -2 and -9 are soluble MMPs which
are secreted into the extracellular environment. Therefore, conditioned media from each mutant
of LIMK1 was harvested and analyzed on 10% SDS gel co-polymrized with denatured collagen
(gelatin). Our results showed a graded amount of secreted latent MMP2 (72kD) with the
maximum, intermediate and least secretion observed in BPHLCA, BPHLKD, and BPHLK cells
respectively (Figure 20). BPHLK cells showed the highest level of latent MMP-9 (92kDa),
(Figure 21). No secretion of latent MMP9 was observed in the media of BPHLCA, BPHLK D and
BPHV cells.
Quantification of mRNA Concentration
To determine whether LIMK1 expression alters the steady state mRNA concentration of matrix
metalloprotease -2, quantitative real-time PCR was done using total RNA from the transfected
BPHLCA and BPHV cells. The results showed that the mRNA concentration of MMP-2 was~10
fold higher than BPH cells expressing the vector (BPHLV) (Figure 22). The concentration of
MT1-MMP mRNA was unchanged between LIMK1 over expressing samples and BPHV cells.
No difference in the concentration of MT1-MMP mRNA was noted between BPHLCA and BPHV
cells. Therefore the upregulation of MT1-MMP observed in cells expressing constitutively
active LIMK1 appears to take place at the level of activation level. The house keeping gene,
GAPDH was used as a reference.
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Figure 20 Gelatin zymography of the secreted Matrix Metalloproteinase 2
(A): Expression of secreted Pro-MMP-2 in transfected BPH cell lines. BPH cells expressing constitutively active
LIMK1(BPHLCA) had the highest concentration of Pro-MMP-2. BPHLKD (kinase dead) and BPHLK cells showed
also showed comparable levels of secreted Pro-MMP-2 but substantially lower than BPHLCA cells. BPHV cells
showed the least amount of secreted. (B): Densitometric analysis of relative intensity of gelatinoic activity. Values
are mean +/- SE of three experiments. * P=0.028, ** P=0.035*** P=0.010 when compared to control (BPHV)
cells.
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Figure 21 Gelatin zymography of secreted Matrix metalloproteinase 9
(A) BPHL cells expressing only the kinase domain of LIMK1 (BPHLK), had the maximum amount of secreted ProMMP-9. Transfected BPHLCA, BPHLKD cells showed significantly lower concentrations of secreted Pro-MMP-9.
BPHV cells had the least amount of secreted pro-MMP-9(B): Densitometric analysis of the relative intensity of
gelatinoic activity. Values are mean +/- SE of three experiments. * P=0.002, ** P=0.018*** P=0.001 when
compared to control (BPHV) cells.
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Figure 22 Quantitative Real-time PCR analysis of MMP-2 steady state mRNA
BPH cells expressing constitutively active LIMK1 had 10 fold increase in MMP-2 mRNA
concentration relative to vector only control cell line (BPHV). Normalized average ∆CT values
for BPHV and BPHLCA were -7 and -3.7, respectively. Values are means +/- SE of three
experiments.
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3.4 MT1-MMP Expression positively Correlates with the Concentration of active LIMK1
Ectopic Expression of Constitutively Active LIMK1 Increased MT1-MMP Expression
Membrane type I-matrix metalloproteinase is known to activate MMP-2 and possibly MMP-9.
Furthermore, because it has potent pericelluar ECM degrading activity, MT1-MMP is one of the
most important regulators of cell migration and invasion.

Upon activation of MT1-MMP

through cleavage of the pro-peptide by furin like convertases, it is inserted into the plasma
membrane (Figure 5a). To analyze whether there is any change in the cell surface expression of
MT1-MMP, an antibody was used that recognizes the catalytic domain of MT1-MMP, the
domain exposed to the extra cellular side of the plasma membrane. Flow cytometric analysis
indicated that the BPHLCA cells expressed the highest amount of MT1-MMP on the surface
(Figure 23).

BPHLKD cells expressing catalytically inactive LIMK1 also showed modest

increase in the cell surface expression of MT1-MMP compared to BPHV control cell.
Expression of MT1-MMP in BPHLK and BPHV cell lines were comparable but lower than that of
BPHLCA and BPHLKD. Because MT1-MMP is targeted to the plasma membrane in it’s active
form, increased surface expression of MT1-MMP could be considered as increased activity of
MT1-MMP. Therefore, it could be inferred that increased expression of active LIMK1 increased
the activity of MT1-MMP in BPHLCA cells. For densitometric analysis, the cells that were
emitting fluorescence were gated out from the nonfluorescent cells and calculated as the
percentage of the control (BPHV) cells (Figure 24).
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BPHV

BPHK

BPHKD

BPHCA

Figure 23 Flow cytometric analysis of MMP-14 cell surface expression in transfected BPH cell lines.
Two parameter histograms with fluorescence intensities in the X axis and number of cells in the Y axis. A total of
10.000 cells were counted. Black histogram represents unstained cells, red histrogram represents population of
fluorescent cells within each sample. Data shows a noticeable shift in the red histogram of BPHLCA cells
representing high number of cells with fluorescence. The red histogram of BPHLKD cells also showed a shift
towards the right representing increased number of cells with fluorescence compared to that of BPHV cells. Red
histogram of BPHV cells showed minimum shift indicating minimal number of fluorescent cells. A modest shift in
the red histogram was noted in BPHLK cells representing fluorescent cells with some degree of MT1-MMP
expression.
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Figure 24 Relative Expression of MT1-MMP in BPH cells expressing different domains of
LIMK1.
Quantitative analysis of flourescent cells after elimination of cell debris and non-flourescent
cells. Data represents the average +/- SE of three independent experiments. * P=0.136, **
P=0.109 and *** P=0.05.
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Expression of LIMK1 Transgenes Increased Concentration of MT1-MMP
Total protein were extracted from LIMK1 expressing cell lines and analyzed by western blots
using anti-MT1-MMP antibody. . The results showed a considerable increase in MT1-MMP
latent and active protein levels in BPHLCA cell line compared to the vector only control cell line
BPHV (Figure 25). As a positive control PC3 extracts were used as they express high levels of
MT1-MMP [Daja et al., 2003]. The level of MT1-MMP observed in BPHLKD was comparable
to but less than that of BPHLCA. BPHLK cells showed the least amount of MT1-MMP. The
vector only cell line (BPHV) did not express any MT1-MMP. This data also substantiates a
positive correlation between LIMK1 and MT1-MMP protein levels.
MT1-MMP Co-localizes with LIMK1 in the Perinuclear Region
To determine the intracellular localization of MT1-MMP, dual label immunoflourescence using
antibodies of MT1-MMP and Flag was performed. A distinct difference in cell morphology was
noted in cells expressing active LIMK1, kinase dead LIMK1 and only the kinase domain.
Lamellipodia and filopodia extensions were observed in constitutively active (BPHLCA) cells
(Figure 26).

Cellular morphology and localization pattern of MT1-MMP in BPH cells

expressing LIMK1 with intact LIM domains (BPHLCA and BPHLKDcells) were comparable,
although more ruffling membranes were noted in BPHLCA cells. In BPHLK cells, microspikes
were observed.
phenotype.

Also, BPHLK cells were clustered together and showed a more adherent

Higher concentration of MT1-MMP was also observed in BPHLCA cells.

In

addition, co-localization of MT1-MMP and constitutively active LIMK1 to the perinuclear
region was most evident in BPHLCA cells. Flag staining observed in was BPHV was essentially
non-existant compared to BPHL sublines.
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Figure 25 Expression of Pro-MT1-MMP and active MT1-MMP in BPH-LIMK cell lines
Western blot analysis of MT1-MMP in BPH crude extracts of expressing LIMK1 mutants.
Metastatic prostate cancer cells (PC3) that express high levels of LIMK1, also showed
expression of latent and active MT1-MMP.
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Merge

Figure 26 MT1-MMP localization studies of BPH cells expressing mutant LIMK1
In BPHLK cells diffused cytoplasmic and nuclear localization of LIMK1 (green) and appearance
of microspikes (arrow) could be seen. Localization of MT1-MMP in these cells was mainly to
the perinuclear region. In BPHLKD cells, LIMK1 was localized to the nuclei and to the plasma
membrane (arrow). BPHLKD merged image shows that MT1-MMP is distributed throughout the
cytoplasm and co-localized with LIMK1 (arrow). In BPHLCA cells, increased concentration of
constitutively active LIMK1 to the plasma membrane was evident. Appeaance of lamellipodia
also could be seen in these cells. BPHLCA cells, showed the most intense staining of MT1-MMP
and accumulation of LIMK1 to ruffling membranes (merged image, arrows).
MT1-MMP localization was observed in the perinuclear to cytoplasmic region in BPHLCA and
BPHLKD cell lines. However, in BHPLKD cells, MT1-MMP staining was more concentrated to
the perinuclear region. Further, the results showed modest co-loclization between constitutively
active LIMK1 and MT1-MMP in the membrane ruffles.
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3.5 Phospho-LIMK1/2 Associates with γ-Tubulin
Role of LIMK1 in Mitosis
Disruption of highly orchestrated processes like mitosis and cytokenesis causes chromosomal
instability and subsequent tumor progression [Ohbayashi et al., 2007]. In addition, LIMK1 has
been shown to coordinate microtubule instability through co-localization with microtubules and
complex formation via PDZ domain [Gorovoy et al., 2005].

Induction of microtubule

destabilization by treatment with nocodazole resulted in decreased association with LIMK1.
Because centrosomes are critically involved in mitotic spindle formation we studied the
distribution of phospho-LIMK1/2 in the mitotic cells.
Co-localization studies of p-LIMK1/2 and γ-tubulin
Immunoflourescence analysis of metastatic (MDA-MB-231) and normal (HMEC) breast
epithelial cells (HMEC) revealed that phospho-LIMK1 and γ-tubulin co-localize to the
centrosome during prophase, metaphase and anaphase (Figure 8). This pattern of localization
was also observed in the invasive prostate cancer cell line DU145 (data not shown). This colocalization diminishes at the onset of telophase. Visualization of phospho-LIMK1 and γ-tubulin
localization was accomplished using a monoclonal α-gamma tubulin and polyclonal α-phosphoLIMK1 antibodies. To determine optimal dilution of phospho-LIMK1/2 to be used in western
blot analysis, both antibodies were titrated using crude nuclear extracts of LNCap and BPH
whole cell extracts (Figure 27). Western blot analysis showed that 1:50 was the optimal dilution
to use for 50ug of nuclear extracts. Immunoprecipitation with γ-tubulin antibody pulled down
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Figure 27 Titration of phospho-LIMK1/2 antibody in BPHL cells
(A) Titration of p-LIMK1. (B) Titration of and p-LIMK2. GAPDH was used as a loading
control. Fifty microgram of crude BPH extracts were used.
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Figure 28 Biochemical interactions between phospho-LIMK1 and γ-tubulin
Panel (A) Upper and middle panel: Western blot analysis of p-LIMK1and p-LIMK1 in crude
nuclear extracts and immunoprecipitates with γ-tubulin antibody using MDA-MB-231 cells.
Lower panel: Treament of MDA-MB-231 cells with CIAP or immunoprecipiton with nonspecific antibody followed by western blot analysis with anti-phospho-LIMK1. Panel (B):
Western blots of p-LIMK1, γ-tubulin and Flag-tagged LIMK1 in crude and γ-tubulin
immunoprecipitates of nuclear extracts of BPHLFLAG cells. Panel (C) Western blots of p-LIMK1
and γ-tubulin in Flag immunoprecipitates of nuclear extracts of BPHFLAG cells.
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phospho-LIMK1. This interaction between γ-tubulin and p-LIMK1/2 was shown to exist in BPH
cells over expressing LIMK1 and MDA-MB-231 breast cancer cells (Figure 28a/b). To confirm
that γ-tubulin specifically associated with phospho-LIMK1, nuclear extracts were treated with
calf intestinal alkaline phosphatase (CIAP). Treatment with CIAP removes phosphate groups
from all phosphorylated protein. Therefore CIAP treated nuclear extracts did not precipitate with
γ-tubulin as indicated by post immunoprecipitation immunoblot analysis (Figure 28a). This
confirms

that

γ-tubulin

associates

with

LIMK1

only

in

phosphorylated

form.

Immunoprecipitation with an unrelated antibody showed that γ-tubulin was specifically
associating with p-LIMK1 (Figure 28a). In addition, immunoprecipitation with Flag antibody
also pulled down γ-tubulin and phospho-LIMK1 (Figure 8c). Therefore recombinant LIMK1
expressed in BPH cells is also associating with γ-tubulin.
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4. DISCUSSION
4.1 LIM kinase 1 and Matrix metalloproteases
LIM kinase 1 has been identified as a required component for the invasion of prostate
epithelial cells [Davila et al., 2003]. To determine the structure-function relationship of LIM
kinase 1 mediated invasion, mutant constructs were designed. BPH cells stably over expressing
a kinase domain only mutant of LIM kinase 1 (BPHLK) showed decreased invasiveness when
compared to kinase dead mutant (BPHLKD) and constitutively active mutant (BPHLCA) of LIM
kinase 1. The percent invasion for BPHLCA and BPHLKD cell lines were comparable. The
kinase domain only of LIMK1 mutant did not promote invasion of BPH cells. Phosphorylation
of LIMK1 at T508 allows dissociation of the LIM domains from the kinase domain. When LIM
kinase 1 becomes phosphorylated, it ‘s conformation changes from closed to open, thereby
making the LIM domains accessible (Figure 7). Therefore it is reasonable to assume that the
highly invasive phenotype seen in BPHLCA cell line may be due to increased protein:protein
interactions involving the LIM and/or the PDZ domain., kinase activity, or both. In fact, current
studies showed a correlation between the protein:protein interaction of LIM domain containing
proteins PELP1 and FHL2 with prostate cancer progression [Nair et al., 2007]. This data suggest
that the LIM domains of LIM kinase 1 may be necessary for the invasiveness of cancerous
prostate. This result further implies that LIM kinase 1 is able to induce invasion independent of
it’s kinase activity. While there is conflicting evidence as to the role of LIM kinase 1 in
promotion or inhibition of tumor cell invasion [Wang et al., 2006], the data presented here
supports a pro-invasive role for LIM kinase 1 in the absence of it’s kinase activity in prostate
epithelial cells. In addition, little is known about the mechanism by which LIM kinase 1 exerts
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it’s effect. However, research from other laboratories showed that the regulation of cofilin by
LIMK1 is central to LIM kinase 1 mediated invasiveness [Zebda et al., 2000]. The reason for
these opposite findings is not known. However, based on this study, one can speculate that there
may be interacting proteins associated with the LIM and PDZ domains, which are in part
responsible for invasion, and that the activity of LIM kinase 1 contributes to invasion but is not
necessary for invasion.
To understand the mechanism underlying LIM kinase 1 mediated invasion we monitored
the effect of inhibition of matrix metalloprotease 2/9 on the ability of BPH-LIMK1 cell lines to
invade matrigel coated membrane in vitro. Because MMPs have been shown to be involved in
prostate cancer cell invasion [Wilson et al., 2004], we hypothesized that they may also be
involved in LIM kinase 1 mediated prostate cancer cell invasion. Inhibition of MMPs resulted in
considerable decrease in invasion of BPH cells expressing kinase dead or active LIMK1 through
matrigel coated membranes. Matrix metalloprotease inhibition had the greatest effect on BPH
cells expressing active LIMK1.

There is substantial evidence implicating matrix

metalloprotease-2 and matrix metalloprotease-9 as key enzymes in prostate cancer cell invasion,
[Vayalil and Katiyar, 2004], [Vijayababu et al., 2006], [Sehgal and Thompson, 1999], [Hong et
al., 2006]. In agreement with published reports, we found that MMP-2 and MMP-9 are involved
in the invasion of prostate epithelial cells. However, to our knowledge, our study provides novel
data that links the expression of LIM kinase 1 activity to the expression of matrix
metalloproteases. Gelatinase zymography analysis showed that the BPHCA cell line produced the
highest concentration of secreted latent MMP-2. Conversely, the highest concentration of MMP9 was seen in BPHK cell line. Comparable concentration of secreted latent MMP-2 was observed
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in BPHKD. In comparison, BPH cells stably expressing kinase dead (BPHK) or the vector
(BPHV) had minimal levels of latent MMP-2.

These data further confirms that MMPs have an

integral role to play in prostate cancer cell invasion. It also showed a positive correlation
between LIM kinase 1 induced expression and the secretion of soluble MMP-2. It could be
speculated that LIM kinase 1 may have a role in either the expression, regulation, or activation of
MMP-2
Quantitative RT-PCR data showed that LIMK1 is involved in alteration of the mRNA
levels of MMP-2. We used BPH cells expressing constitutively active LIMK1 or vector only.
The results show a 10 fold increase in the steady state mRNA levels of MMP-2 in BPH cells
over expressing LIM kinase 1 relative to the vector control. GAPDH was used as a reference
gene. These results showed that LIM kinase 1expression increased the steady state level of
MMP-2 mRNA compared to control BPH cells. Our data on MMP-2 and MMP-9 expression in
prostate cancer cells provides further evidence to support current knowledge [Aalinkeel et al.,
2004; Pratap et al., 2005; Singh et al., 2004] and also extends the understanding by linking
MMP-2 and MMP-9 expression to LIM kinase 1. Our data supports our hypothesis that LIM
kinase 1 induced invasion is mediated by MMPs . And further, this correlation is seen at the level
of mRNA concentration and protein expression.
Membrane-type I matrix metalloprotease is vital for initiation of ECM degradation
[Udayakumar et al., 2004], [Bair et al., 2005], [Golubkov et al., 2005]. MT1-MMP (also called
MMP-14) not only directs the degradation of cell surface ECM, but also activates MMP-2,
another potent ECM degrading family member [Dong et al., 2005], [Cardillo et al., 2006]. Using
flow cytometric analysis we were able to quantitate the level of “processed” MMP-14 at the
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plasma membrane in benign prostate epithelial cells. In addition, our results showed that upon
treatment with EGF there was a considerable increase in MT1-MMP signal intensity compared
to samples not treated with EGF (data not shown). This result complies with current research
that identifies EGF signaling as an upregulated pathway in prostate cancer [Mimeault et al.,
2007b], [Angelucci et al., 2006]. It is logical to assume that EGF signaling increases the level of
active endogenous LIM kinase 1 mediated by Rac 1 while simultaneously inducing MT1-MMP
expression [Kheradmand et al., 2002], [Van Meter et al., 2004] [Yeh et al., 2006]. In addition,
EGFR signaling increases the activation of both LIM kinase 1 and MT1-MMP in prostate cancer
cells. In this study, we show increased expression of MT1-MMP on the cell surface in BPH cells
stably expressing constitutively active LIM kinase 1. Cell lines expressing, kinase dead and
kinase domain mutants of LIM kinase 1, showed comparable levels of MT1-MMP expression
relative to the control. Since MT1-MMP is only inserted into the plasma membrane after
cleavage and activation by furin convertases , [Hernandez-Barrantes et al., 2000] we can argue
that over expression of LIM kinase 1 correlates with increased expression and increased activity
of MT1-MMP.
Immunoflourescence analysis revealed that LIM kinase 1 and MT1-MMP co localize to
the perinuclear to cytoplasmic region in BPH. Current research shows that MT1-MMP targeting
to the plasma membrane is necessary for migrating cells to become invasive [Strongin, 2006].
Cell lines expressing constitutively active and kinase dead mutants showed distinct formation of
lammellipodia and membrane ruffles upon treatment with EGF. However a dramatic effect was
seen in cells expressing constitutively active LIM kinase 1. In addition, co-localization of LIM
kinase 1 and MT1-MMP in the membrane ruffles was observed in BPHLCA. This data suggest
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that LIM kinase 1 and MT1-MMP are both involved in the formation of structures relevant to
tumor cell motility and that these enzymes may be functionally or mechanistically related. We
can also infer that sub cellular localization of MT1-MMP is in part dependant on LIM kinase 1
expression and/or activity. BPH cells expressing only the kinase domain showed substantial
formation of micro spikes; which are consistent with Rho signaling effects [Aznar et al., 2004].
No specific localization was seen in the control cell line expressing the vector. Our localization
studies focused on LIM kinase 1 and MT1-MMP support the hypothesis that LIM kinase 1
induced invasion is mediated by matrix metalloproteases.

Moreover, we provide further

evidence in support of the current knowledge that MT1-MMP is involved in the migration of
cancer cells [Lehti et al., 2000]. MT1-MMP and LIM kinase 1 may act synergistically to each
other in the process of tumor cell migration and invasion.
The work presented here is important because it expounds on the key molecules that are
involved in prostate cancer cell progression to invasiveness. Matrix-metalloproteinase’s are
extra cellular matrix degrading enzymes with clear and direct links to malignancy [Nelson et al.,
2000]. Independantly, LIM kinase 1 and matrix metalloproteases expressions have been strongly
implicated with increasing malignancy Our study shows that there may be cross-talk between
these two proteins in promotion of invasion. This study also provides evidence that LIM kinase 1
mediated invasion can occur independent of it’s kinase activity. The data also indicate that in the
absence of the LIM domains, BPH cells showed considerably decreased invasiveness. This
strongly indicates the LIM domains are critical to the invasiveness of LIM kinase 1. To confirm
this speculation, a mutant of LIM kinase 1 that is both kinase dead and constitutively open can be
studied. Taken together these results elucidate the mechanisms involved in prostate cancer cell
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invasion by linking LIM kinase 1 to MMPs. Both of which are independently known to be
involved in tumor cell migration and invasion. Identification of molecular drug targets for tumor
cell invasion relies on the elucidation of the complex mechanism of metastasis. This data
provides evidence that LIM kinase 1 could be a target for anti-metastatic drug that could possibly
effect the matrix metalloproteinase’s. In addition, Meng et al have shown that knockout LIM
kinase 1 mice display only minor abnormalities; hence LIM kinase 1 represents an ideal target
for drug design [2002].
4.2 LIM KINASE 1 and γ-Tubulin
LIM kinase 1 is well established as a potent regulator of the actin cytoskeleton through
it’s interaction with cofilin [Zebda et al., 2000]. Previous studies have revealed that LIM kinase
1 has a role in the stabilization of microtubules [Gorovoy et al., 2005]. Cell motility, migration
and division are processes that rely on the coordination between microtubules and actin
cytoskeleton [Rodriguez et al., 2003]. Sumi et al showed that LIM kinase 1 activation and
subsequent targeting to the spindle pole is regulated by cell cycle progression in HeLa cells. The
data presented here further supports these findings. During interphase, epiflourescence imaging
showed that phospho-LIM kinase 1 is not co-localized with γ-tubulin. However upon activation
and the onset of mitosis a distinct localization is seen between γ-tubulin and phospho-LIM
kinase1 to the spindle poles. This p-LIM kinase 1/γ-tubulin association was abolished during
telophase where p-LIM kinase 1 concentrated to the cleavage furrow.

This pattern of

localization between p-LIM kinase 1 and γ-tubulin was observed in the slightly metastatic
prostate cancer cell line DU-145, in the highly invasive breast cancer cell line MDA-MB-231
and in normal benign breast cancer cells, HUMEC. This indicates that this interaction is not
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cancer cell specific and that it may represent a novel role for LIM kinase 1 in the regulation of
cell division. We propose that inactive LIM kinase 1 is bound to microtubules during interphase
and when it becomes phosphorylated it is released from microtubule and targeted to the
centrosome where it associates with γ-tubulin.

Other studies showed a similar cell cycle

dependant activation of Ajuba (a LIM containing protein) and subsequent co-localization with γtubulin to the centrosome [Abe et al., 2006].
Immunoprecipitation reactions confirmed that p-LIM kinase 1 associates with γ-tubulin
Nuclear extracts of BPH and MDA-MB-231 immunoprecipitated with γ-tubulin and blotted with
p-LIM kinase 1 gave a positive result.

Western blot analysis of nuclear extracts

immunoprecipitated with a un-related antibody could not be detected by probing with antiphospho-LIMK1. Similarly, nuclear extracts immunoprecipitated with non-specific antibody
and immuno blotted with p-LIM kinase 1 antibody did not yield a signal. This result confirms
that p-LIM kinase 1 is specifically associating with γ-tubulin. To prove that p-LIM kinase 1 and
not LIM kinase 1 is associating with γ-tubulin, nuclear extracts were treated with calf intestinal
alkaline phosphatase (CIAP) to remove phosphate group from all proteins. CIAP treated extracts
were processed and showed no band after immunoblotting with p-LIM kinase 1. It is important
to mention that p-LIM kinase 2 also associated with γ-tubulin. This result suggest that p-LIM
kinase 1 may have an indirect role in mitotic spindle assembly through its interaction with γtubulin at the centrosome during prometaphase to anaphase. Therefore over expression of
LIMK1 in cancer cells may promote chromosomal instability and spindle defects.
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